Amixicile Inhibits Anaerobic Bacteria within an Oral Microbiome Derived from Patients with Chronic Periodontitis by Ramsey, Kane
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2017 
Amixicile Inhibits Anaerobic Bacteria within an Oral Microbiome 
Derived from Patients with Chronic Periodontitis 
Kane Ramsey 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Pathogenic Microbiology Commons, and the Periodontics and Periodontology Commons 
 
© The Author Kane W. Ramsey 
Downloaded from 
https://scholarscompass.vcu.edu/etd/4862 
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has 
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. 
For more information, please contact libcompass@vcu.edu. 
© Copyright by Kane W. Ramsey 2017 
All Rights Reserved 
 
ii 
 
 
 
Amixicile Inhibits Anaerobic Bacteria within an Oral Microbiome 
Derived from Patients with Chronic Periodontitis 
 
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Dentistry at Virginia Commonwealth University. 
 
 
 
By 
 
 
Kane W. Ramsey 
BS University of Mary Washington, Fredericksburg 2008, DMD TUSDM 2014 
 
 
 
Director: Dr. Janina P. Lewis, Director of Faculty Advancement, Professor of Oral and 
Craniofacial Molecular Biology, Philips Institute, School of Dentistry 
 
 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
April 3, 2017 
 
iii 
 
 
 
Acknowledgment 
 
 
 
The author would like to thank her Research Committee of Dr. Janina Lewis, Dr. Harvey 
Schenkein, Dr. Thomas Waldrop for providing both insight and oversight with this project, and 
especially Dr. Best, for his work with the statistics.  
iv 
 
 
 
Table of Contents 
INTRODUCTION ........................................................................................................................ 12 
MATERIALS AND METHODS .................................................................................................. 17 
Study Population .................................................................................................................. 17 
Biofilm Sample Collection .................................................................................................. 18 
Antimicrobial Treatment ...................................................................................................... 18 
Propidium monoazide (PMA) Treatment ............................................................................ 19 
DNA isolation and qPCR ..................................................................................................... 19 
DNAseq library generation .................................................................................................. 19 
Statistical Analysis ............................................................................................................... 20 
RESULTS ..................................................................................................................................... 21 
Plaque Harvest and Growth ................................................................................................. 21 
Total Bacteria in Sample (Non-PMA) Runs ........................................................................ 23 
Levels of Live Bacteria within Sample : (PMA) Runs ........................................................ 29 
Comparison of levels of live and dead bacteria within microbiome ................................... 34 
DISCUSSION ............................................................................................................................... 36 
CONCLUSIONS........................................................................................................................... 45 
Literature Cited ............................................................................................................................. 46 
Appendices .................................................................................................................................... 53 
v 
 
 
Amixicile targets specific anaerobic bacteria that utilize the pyruvate-ferredoxin 
oxidoreductase pathway (PFOR) ......................................................................................... 53 
Guidelines for the diagnosis of periodontitis according to the American Academy of 
Periodontology 2015 ............................................................................................................ 54 
Run 2017-02-28_144220 ..................................................................................................... 55 
Run 2017-03-07_1 ............................................................................................................... 61 
Run 2017-03-21_162558 ..................................................................................................... 67 
Run 2017-04-13_175325 ..................................................................................................... 73 
Non-PMA Runs ................................................................................................................... 79 
Run 2017-02-28_pma .......................................................................................................... 81 
Run 2017-03-07_pma .......................................................................................................... 87 
Run 2017-04-13_184418PMA............................................................................................. 93 
PMA Runs ............................................................................................................................ 99 
 
 
vi 
 
 
 
List of Tables 
Table 1. Corrected CT mean estimates for non-PMA Runs ......................................................... 25 
Table 2. Fold change for non-PMA Runs ..................................................................................... 27 
Table 3. Corrected CT mean estimates for PMA Runs ................................................................ 30 
Table 4. Fold estimates for PMA Runs ......................................................................................... 32 
Table 5. Corrected CT mean estimates for Run 2017-02-28_144220 .......................................... 55 
Table 6. Differences in the Corrected CT mean estimates for Run 2017-02_28_144220 ............ 57 
Table 6. Fold estimates for Run 2017-02-28_144220 .................................................................. 59 
Table 7. Corrected CT mean estimates for Run 2017-03-07_1 .................................................... 61 
Table 9. Differences in the Corrected CT mean estimates for Run 2017-03-07_1 ...................... 63 
Table 8. Fold change for Run 2017-03-07_1 ................................................................................ 65 
Table 9. Corrected CT mean estimates for Run 2017-03-21_162558 .......................................... 67 
Table 12. Differences in the Corrected CT mean estimates for Run 2017-03-21_162558 .......... 69 
Table 10. Fold change for Run 2017-03-21_162558 .................................................................... 71 
Table 11. Corrected CT mean estimates for Run 2017-04-13_175325 ........................................ 73 
Table 15. Differences in the Corrected CT mean estimates for Run 2017-04-13_175325 .......... 75 
Table 12. Fold estimates for Run 2017-04-13_175325 ................................................................ 77 
Table 17. Differences in the Corrected CT mean estimates for non-PMA Runs ......................... 79 
Table 18. Corrected CT mean estimates for Run 2017-02-28_pma ............................................. 81 
Table 19. Differences in the Corrected CT mean estimates for Run 2017-02-28_pma ............... 83 
Table 19. Fold estimates for Run 2017-02-28_pma ..................................................................... 85 
Table 21. Corrected CT mean estimates for Run 2017-03-07_pma ............................................. 87 
vii 
 
 
Table 22. Differences in the Corrected CT mean estimates for Run 2017-03-07_pma ............... 89 
Table 22. Fold estimates for Run 2017-03-07_pma ..................................................................... 91 
Table 24. Corrected CT mean estimates for Run 2017-04-13_184418PMA ............................... 93 
Table 25. Differences in the Corrected CT mean estimates for Run 2017-04-13_184418PMA .. 95 
Table 26. Fold estimates for Run 2017-04-13_184418PMA ........................................................ 97 
Table 27. Differences in the Corrected CT mean estimates for PMA Runs ................................. 99 
 
viii 
 
 
 
List of Figures 
Figure 1. Comparison of Bacteria in Baseline Sample and 24 hour culture ................................. 22 
Figure 2. Corrected CT mean estimates for non-PMA Runs ........................................................ 26 
Figure 3. Fold change for non-PMA Runs (95% CI) .................................................................... 28 
Figure 4. Corrected CT mean estimates for PMA Runs (95% CIs) .............................................. 31 
Figure 5. Fold estimates for PMA Runs (95% CIs) ...................................................................... 33 
Figure 6. This figure displays how amixicile targets specific anaerobic bacteria by blocking the 
PFOR metabolic pathway. ...................................................................................................... 53 
Figure 7. Classification of Periodontal Disease Severity .............................................................. 54 
Figure 8. Corrected CT mean estimates for Run 2017-02-28_144220 (95% CIs) ....................... 56 
Figure 9. Differences in the Corrected CT mean estimates for Run 2017-02_28_144220 (95% 
CIs) .......................................................................................................................................... 58 
Figure 10. Fold estimates for Run 2017-02_28_144220 (95% CIs) ............................................. 60 
Figure 11. Corrected CT mean estimates for Run 2017-03-07_1 (96% CIs) ............................... 62 
Figure 12. Differences in the Corrected CT mean estimates for Run 2017-03-07_1 (95% CI) ... 64 
Figure 13. Fold change for Run 2017-03-07_1 (95% CIs) ........................................................... 66 
Figure 14. Corrected CT mean estimates for Run 2017-03-21_162558 (95% CI) ....................... 68 
Figure 15. Differences in the Corrected CT mean estimates for Run 2017-03-21_162558 ......... 70 
Figure 16. Fold change for Run 2017-03-21_162558 (95% CI) .................................................. 72 
Figure 17. Corrected CT mean estimates for Run 2017-04-13_175325 (95% CIs) ..................... 74 
Figure 18. Differences in the Corrected CT mean estimates for Run 2017-04-13_175325 ......... 76 
Figure 19. Fold estimates for Run 2017-04-13_175325 (95% CIs) ............................................. 78 
ix 
 
 
Figure 20. Differences in the Corrected CT mean estimates for non-PMA Runs ........................ 80 
Figure 21. Corrected CT mean estimates for Run 2017-02-28_pma (95% CIs) .......................... 82 
Figure 22. Differences in the Corrected CT mean estimates for Run 2017-02-28_pma .............. 84 
Figure 23. Fold estimates for Run 2017-02-28_pma (95% CIs) .................................................. 86 
Figure 24. Corrected CT mean estimates for Run 2017-03-07_pma (95% CIs) .......................... 88 
Figure 25 Differences in the Corrected CT mean estimates for Run 2017-03-07_pma ............... 90 
Figure 26 Fold estimates for Run 2017-03-07_pma (95% CIs) ................................................... 92 
Figure 27. Corrected CT mean estimates for Run 2017-04-13_184418PMA (95% CIs) ............ 94 
Figure 28. Differences in the Corrected CT mean estimates for Run 2017-04-13_184418PMA 96 
Figure 29. Fold estimates for Run 2017-04-13_184418PMA (95% CIs) ..................................... 98 
Figure 30. Differences in the Corrected CT mean estimates for PMA Run ............................... 100 
  
 
 
  
Abstract 
 
AMIXICILE INHIBITIS ANAEROBIC BACTERIA WITHIN AN ORAL MICROBIOME 
DERIVED FROM PATIENTS WITH CHRONIC PERIODONTITIS 
 
By Kane W. Ramsey, DMD 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Dentistry at Virginia Commonwealth University. 
Virginia Commonwealth University 2017 
 
Major Director: Dr. Janina P. Lewis, Director of Faculty Advancement, Professor of Oral and 
Craniofacial Molecular Biology, Philips Institute, School of Dentistry 
 
 
Periodontitis is a chronic inflammatory disease caused by pathogenic bacteria residing in a 
complex biofilm within a susceptible host. Amixicile is a non-toxic, readily bioavailable novel 
antimicrobial that targets strict anaerobes through inhibition of the activity of Pyruvate 
Ferredoxin Oxidoreductase (PFOR), a major enzyme mediating oxidative decarboxylation of 
pyruvate. Our study aimed to evaluate the efficacy of amixicile, when compared to 
metronidazole, in inhibiting the growth of bacteria present in a microbiome harvested from 
patients with chronic periodontitis.  
 
Plaque samples were harvested from patients with severe chronic periodontitis and cultured 
under anaerobic conditions. The microbiomes were grown in the presence of amixicile and 
metronidazole and the growth was compared to that of bacteria grown in the absence of the 
  
 
antimicrobials. Following 24 hour growth the bacterial DNA was analyzed using quantitative 
PCR (qPCR) using primers specific for 12 bacterial species: P. gingivalis (Pg), P. intermedia 
(Pi), F.nucleatum (Fn), S.gordonii (Sg), S. anginosus (Sa), V. atypical (Va), L. acidophilus (La), 
A.actinomycetemcomitans (Aa), T.denticola (Td), S.mutans (Sm), and S.sanguis (Ss).  
 
Both drug treatment groups yielded a statistical significant reduction for several anaerobic 
bacteria: Pi (P<.001), Fn (P<.001), Va (P<.001), and La (P<.001). Results indicated that 
amixicile and metronidazole had an effect on PFOR-containing bacteria and amixicile performed 
with similar efficacy to that of metronidazole. In conclusion, amixicile targets and reduces the 
quantities of anaerobic bacteria within an oral microbiome, and could be a potential new 
therapeutic antimicrobial in the treatment of periodontal disease. 
 
Keywords: amixicile, metronidazole, micobiomes, periodontitis, q-PCR analysis 
 
 INTRODUCTION 
Periodontitis is a chronic inflammatory disease caused by bacteria that colonize either at or 
below the gingival margin [1]. As plaque accumulates around teeth, it causes the inflammatory 
system to produce a wide array of cytokines, which are ultimately responsible for the destruction 
associated with disease. Unlike gingivitis, which is a reversible gingival inflammatory condition; 
periodontitis leads to the eventual breakdown of the junctional attachment apparatus to the tooth 
[1,2]. The types of clinical features seen in periodontitis are clinical attachment loss, 
radiographic bone loss, periodontal pockets, bleeding upon probing, suppuration upon probing, 
and varying degrees of tooth mobility [1]. The most recent data from the National Health and 
Nutrition Examination Survey (NHANES) suggest that the prevalence of chronic periodontitis 
exceeds 47% of U.S. adults [3].  
 
Classic studies have demonstrated clear evidence to link dental plaque and calculus as major 
etiologic agents in the progression of periodontal disease [4,5]. Bacteria found in the oral cavity 
are extremely complex, with over 700+ species living amongst themselves in a layered 
ecosystem that enables them to be pathogenic [6]. Living in a biofilm enables the bacteria to 
receive nutrients, offers protection, and gene transfer. As the quantity of bacteria increase in the 
oral cavity, there is a shift in the types of microflora seen [6]. In health, the predominant bacterial 
species is aerobic Gram + cocci which includes the Streptococcus species [6]. However, in 
periodontitis the predominant species are anaerobic Gram – rods which include organisms such 
as Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Tannerella 
forsythia [6].  
 
  
 
Ultimately periodontal disease is multifactorial.  It is the result of the interplay between specific 
pathogenic bacteria, host risk factors, and host-immune response. As microbiota dysbiosis occurs 
in subgingival plaque surrounding teeth, specific inflammatory pathways are activated in the host 
[4,5,6,7]. Once the microbiome is dominated by gram – anaerobic bacteria, the host immune 
system mounts a massive inflammatory response in an attempt to heal [56]. As a result, the 
destruction of the periodontium seen in periodontal disease is caused by the complex relationship 
between pathogenic bacteria that invade the oral biofilm and the types of immune responses 
generated within a susceptible host [56]. 
 
The first phase of treatment in periodontal disease is typically focused on mechanical therapy, 
which aims to reduce total numbers of all bacteria present at the site of infection. Clinicians will 
use a variety of hand instruments and ultrasonic devices to debride the teeth and soft tissues. 
Studies have confirmed that scaling and root planning accompanied with improved oral hygiene 
practices will allow for improvements in periodontal parameters [7]. Yet, the ability to 
effectively clean a diseased root surface is dependent upon multiple factors such as initial pocket 
depth, single versus multi-rooted teeth, and intrinsic anatomy of the tooth [8,9,10,11]. Generally 
speaking the deeper the probing depth the less likelihood of complete removal of etiologic agents 
of plaque and calculus [12]. Furthermore despite meticulous mechanical therapy, persistent 
bacteria can remain due their ability to invade host cells, survive and replicate, and then serve as 
a reservoir for future re-infections [13,14,15,16]. Some bacteria are also capable of altering the 
immune response of the host, thereby allowing them to be evasive [16].  
 
  
 
Based on the infectious nature of periodontal disease, some clinicians have advocated for the use 
of antibiotics in their therapy as an adjunct method to control the bacterial load. The concept is 
based on the premise that there are specific types of bacteria associated with disease and 
therefore employing an antibiotic to target them would be beneficial [17,19,21,50-52]. 
Antibiotics target bacteria either by inhibiting bacterial growth (bacteriostatic) or directly killing 
bacteria (bactericidal). Antibiotics need to reach a minimum inhibitory concentration in order to 
be effective. There has been debate on how the concentration can be measured in the oral cavity 
and how much of the delivered systemic antibiotic will reach the gingival crevicular fluid in the 
periodontium [18].  
 
In clinical practice, mainly broad-spectrum antibiotics are used as adjuncts in periodontal 
disease. The major problem with such antibiotics is inhibition of all bacteria present in infected 
sites. However, not all of the bacteria present in the periodontal infection are pathogenic. Use of 
specific antibiotics would spare commensal bacteria that are crucial for homeostasis and target 
solely pathogenic ones [17,19,21,50-52]. However, caveats with antibiotics include patient 
compliance, systemic side effects, and drug resistance. In a study published by Rams in 2014, 
which sought to measure the antibiotic resistance in human chronic periodontitis microbiota, 
researchers found that patients with chronic periodontitis frequently yielded sub gingival 
periodontal pathogen resistance to in vitro concentrations of antibiotics commonly used in 
clinical periodontal practice [20]. Systematic reviews analyzing the benefits of antibiotics in 
combination with mechanical therapy have determined that systemic antibiotics were uniformly 
beneficial in providing improvement in attachment loss when used as adjuncts to scaling and root 
  
 
planing; although they were borderline significance when used as stand alone therapy 
[17,19,21,50-52]. 
 
Antibiotic use is highly varied amongst clinicians and to this day still remains subjective [17]. 
The Academy of Periodontology position paper on systemic antibiotic use set forth guidelines in 
2004, which outline 3 main factors to consider when determining the use of antibiotics; the 
patient, the pathogenic microbiota and the drug. In summary it states that antibiotics should only 
be administered on the basis of clinical need for further treatment, the findings from 
microbiologic testing and the medical status and current medications of the patient [17]. It 
advocates for the conservative use of systemic antibiotics, and that antibiotics will offer the 
greatest benefit to patients who do not adequately respond to initial mechanical therapy [17]. 
Specific antibiotics have been indicated for the treatment of periodontal disease and include: 
amoxicillin, tetracyclines, metronidazole and combination drug therapy. Based on the current 
body of evidence, use of a systemic antimicrobial as an adjunctive therapy alters the microflora 
associated with periodontal disease [50-52]. However insufficient data for implementing optimal 
antibiotic regimens remain un-resolved in the periodontal literature [17, 50-52]. 
 
Certain antibiotics are ideal for periodontal infections based on their ability to target a specific 
type of bacteria, or ability to concentrate in the gingival crevicular fluid. Metronidazole is 
considered the gold standard for anaerobic infections and has been effective in reducing 
pathogens associated with periodontal disease and sparing indigenous bacteria [17,19,39,45-47]. 
By targeting specific anaerobic bacteria associated with disease and leaving commensal aerobic 
bacteria behind, this in theory allows for the biofilm to be modified and return to one that is no 
  
 
longer pathogenic. When compared to a placebo, the administration of metronidazole in 
conjunction with mechanical therapy had a significant improvement in periodontal parameters, 
reduction of gram – bacteria and spirochetes, and reduced the surgical needs of patients treated 
with non-surgical therapy [46,47].  
 
Amixicile is a promising novel antimicrobial that targets strict anaerobes by affecting a major 
metabolic pathway [22-25]. It selectively affects the disease promoting bacteria by affecting 
pyruvate:ferredoxin oxidoreductase (PFOR). PFOR catalyzes the conversion of pyruvate and 
Coenzyme A (CoA) to CO2 and Acetyl-CoA, which is an important component of many 
metabolic pathways found in anaerobic bacteria and parasites. Bacteria such as Porphyromonas 
gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Tannerella forsythia, utilize 
this pathway for energy (Appendices pp.52). This pathway is highly conserved, and therefore 
conceptually it has been proposed that this antimicrobial will not offer resistance [22-25]. In a 
mouse model, amixicile was shown to have an inhibitory effect on Clostridium difficile infection, 
less systemic side effects, and reduced number of resistant bacteria when compared to traditional 
drugs [25]. 
 
Since amixicile was shown to be effective on anaerobic bacteria, we believe that it will also have 
an effect on specific bacteria present in periodontal disease. Our study aimed to evaluate the 
efficacy of amixicile on a complex microbiome harvested from a periodontal pocket of patients 
with chronic periodontitis. Our hypothesis is that within the microbiome model, amixicile will 
selectively inhibit specific pathogens associated with periodontal disease and spare commensal 
  
 
bacteria. We hypothesize that amixicile will selectively inhibit PFOR bacteria and have similar 
effects when compared to metronidazole. 
 
MATERIALS AND METHODS 
 
Study Population 
The Virginia Commonwealth University Institutional Review Board (HM20005374) approved 
this study. All of the samples harvested in this study came from patients of record at VCU 
Graduate Periodontics Clinic. All participants of the study completed a comprehensive 
periodontal exam at the VCU Department of Periodontology, and received informed consent 
prior to plaque harvest. 
Our inclusion criteria for all participants was as follows: 
1. Adult patients (age 21+)  
2. Non-diabetics  
3. The patient cannot have taken antibiotics within the 6 months  
4. Patient has not received periodontal therapy in the 6 months  
5. Non-pregnant patients  
6. Non-smokers  
7. No patients who required premedication prophylaxis   
8. No aggressive periodontitis   
The diagnosis of disease severity was based on full mouth periodontal charting and clinical 
attachment levels, utilizing criteria outlines in Appendices pp. 53. Severe chronic periodontitis 
  
 
was defined as inflammation of the periodontium with attachment loss of 5mm or more in 
conjunction with radiographic bone loss. 
 
Biofilm Sample Collection 
Bacterial samples were harvested from the pocket originating from the mesial of first molars. 
Local anesthesia was provided to all patients for comfort. All sites were air dried, and cotton roll 
isolation was used. Supra-gingival plaque was gently removed from the tooth, so that the free 
gingival margin was not disturbed. The sample was harvested sub-gingivally via a sterile curette 
and stored in 500 µl of SHI medium. The sample was immediately transported into an anaerobic 
chamber and another 500 µl of SHI medium1 was added to lower the oxygen level of the sample. 
The sample was incubated overnight in an artificial atmosphere (composed of 80% N, 10% H, 
and 10% CO2) at 37 oC using a Coy anaerobic chamber (Ann Arbor, MI), and then aliquoted to 
100 µl and stored in -80 oC with 10% of glycerol.   Sample aliquots from ten patients were 
pooled together and aliquoted to 50 µl of each for the following study. 
 
Antimicrobial Treatment 
50 µl of pooled sample was added to 4 mL of BHI with 10% of filtered human serum (Valley 
Biomedical), then separated into four aliqouts. One aliquot was centrifuged and the pellet was 
kept at -20 oC for DNA isolation as baseline. The others were incubated at 37 oC in the anaerobic 
chamber with or without antimicrobial treatment. The concentrations of Amixicile and 
metronidazole (Sigma) used in this study are 25 µg/mL. Pellets from the overnight cultures were 
obtained for DNA preparation.  
 
  
 
Propidium monoazide (PMA) Treatment 
PMA dye (Biotium) was added to 1 mL of overnight culture to a final concentration of 50 µM. 
Samples were incubated in the dark for 5 minutes with occasional mixing, then exposed to light 
for 15 minutes with a 500 W halogen lamp. Pellets were collected for DNA isolation. 
 
 DNA isolation and qPCR 
Cell pellets were re-suspended in 50 mM EDTA containing 10 mg/mL lysozyme and 100 U/mL 
mutanolysin (Sigma) and incubated at 37°C for 1 hr. DNA was isolated using the Wizard 
Genomic DNA purification kit (Promega) according to manufacturer’s instructions. The DNA 
was then used to quantify the presence of bacterial species in the various samples using a 7500 
Fast Real-time PCR machine (Thermo-Fisher). Purified DNA (1 µL) and species-specific 
primers were added to Fast SYBR Green Mastermix (Thermo-Fisher) and run using standard 
cycle conditions: 95°C for 20 sec (1 cycle); 95°C for 3 sec, 60°C for 30 sec (40 cycles). The 
species-specific 16S rDNA primer sequences used in this study are shown in below. The cycle 
threshold (Ct) data were collected and then converted to absolute fold change. 
 
DNAseq library generation 
 
1µg of purified gDNA was fragmented using a Covaris S2 ultrasonicator following the settings 
for Whole-genome Resequencing. ThruPLEX DNA-seq Kit (Rubicon Genomics) was used for 
library preparation according to manufacturer’s instructions. Library samples were run on the 
Bioanalyzer to check the quantity and quality, then processed for next generation sequencing 
through Nucleic Acids Research Facilities in VCU.  
 
  
 
 
16S rDNA primers 
Porphyromonas gingivalis (Pg) 
Pg F: AGGCAGCTTGCCATACTGCG 
Pg R: ACTGTTAGCAACTACCGATGT 
Lactobacillus acidophilus (La) 
La F: 
GGATAGAGGTAGTAACTGGCCTTTATT 
La R: CAGTTTCCGATGCAGTTCCTCG 
Prevotella intermedia (Pi) 
Pi F: CCATCAGGTTATGCTGGGCA 
Pi R: GTTGCAGACCTCAGTCCGAA 
Aggregatibacter actinomycetemcomitans (Aa) 
Aa F: AGTCGGACGGTAGCAGGTAA 
Aa R: GCTTGGTAGGCCTTTACCCC 
Fusobacterium nucleatum (Fn) 
Fn F: CTGGCTCAGGATGAACGC 
Fn R: ATGGGACGCAAAGCTCTCTC 
Treponema denticola (Td) 
Td F: AGCATGCAAGTCGAACGGTA 
Td R: AACTAGCTAATGGGACGCGG 
Veillonella atypica (Va) 
Va F: CGGCTACTGATCATCGCCTT 
Va R: ATCTTAGTGGCGAACGGGTG 
Streptococcus mutans (Sm) 
Sm F: GCACACCGTGTTTTCTTGAGTCG 
Sm R: CGGCTATGTATCGTCGCCTT 
Streptococcus gordonii (Sg) 
Sg F: GCAATTGCACCACTACCAGA 
Sg R: TGCTCGGTCAGACTTTCGTC 
Streptococcus sanguinis (Ss) 
Ss F: ACGCTGAAGAGAGGAGCTTG 
Ss R: GTGAGCCGTTACCTCACCAA 
Streptococcus anginosus (Sa) 
Sa F: GAGTGCTAGGTGTTGGGTCC 
Sa R: 
TGTTCCGAAGAAACTTCCTATCTCT 
16S universal F: 
AGAGTTTGATCCTGGCTCAG 
16S universal R: 
GCTGCCTCCCGTAGGAGT 
 
 
Statistical Analysis 
Each run used three antimicrobials (control, Amixicile, and Metronidazole—each in duplicate) 
with 12 bacterial species (Pg, Pi, Fn, Sg, Sa, Va, La, Aa, Td, Sm, and Ss). The CT values were 
normalized by subtracting each 16s value difference with the non-controls. The corrected CT 
values were analyzed using a mixed-model ANOVA with the following factors: Antimicrobial 
treatment, bacterial species-a repeated, within-sample factor, and the Antimicrobial*Species 
interaction.   
  
 
RESULTS 
 
Plaque Harvest and Growth 
All plaque samples contained enough bacteria to be grown under laboratory conditions. Every 
effort was made to eliminate supragingival plaque through use of a coronal scaling prior to 
subgingival plaque harvest. Due to the diversity within periodontal biofilms, samples were 
pooled together in order to generate a comprehensive diseased microbiome. The growth of 
bacteria under laboratory conditions was another variable that had to be controlled for. The 
growth of the bacteria within the microbiome was examined under various growth conditions 
including different types of media. All of which were tested to establish the optimal growth 
conditions. Once the methodology was consistent, qPCR was used to ensure that bacteria were 
growing under the established anaerobic conditions. Baseline samples were compared to a 24- 
hour culture. Error! Reference source not found. displays a comparison between (B) baseline 
bacterial sample PCR and (C) 24 hour incubation. The lower the CT value, the more bacteria are 
present in the sample. From Error! Reference source not found. there was an increase in all of 
the bacteria tested, which is indicated by a decrease in the CT value.  
 
  
 
  
Figure 1. Comparison of Bacteria in Baseline Sample and 24 hour culture 
Figure 1 displays the comparison of CT values between baseline plaque samples 
harvested and cultured for 24 hours under laboratory conditions. The decrease in CT 
value corresponds to a greater quantity of bacteria in the sample. 
 
qPCR analysis was used to measure the relative quantities of bacteria within the samples. Some 
of the samples were treated with Propidium monoazide (PMA)which is a membrane-impermeant 
dye that selectively penetrates cells with compromised membranes, which can be considered 
dead. Once inside the cells, PMA intercalates into the DNA and can be covalently cross-linked to 
it, which strongly inhibits PCR amplification. We wanted to rule out any differences that might 
occur with our primers binding to total bacteria in sample versus live bacteria in sample. 
 
Four separate biological replicate qPCR runs performed in duplicate under non-PMA conditions. 
All individual qPCR experiments were analyzed and can be found in the Appendices. The data 
was then compiled to represent an average cycle threshold (CT) values. The results of combining 
the four runs are summarized below. There were three separate biological replicate qPCR runs 
0
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performed in duplicate in PMA conditions. All individual non-PMA qPCR experiments were 
analyzed and can be found in the Appendices. The three PMA runs were combined and the data 
is summarized below. In the final portion of the results section, the non-PMA and PMA 
conditions are compared. 
 
Total Bacteria in Sample (Non-PMA) Runs 
The four previous individual runs were analyzed as one combined experiment. This was 
accomplished by adding an additional factor to the ANOVA model: Run ID. This permits each 
run to have a different mean level. Table 1 displays the corrected CT means compiled from the 
four individual qPCR runs. From Table 1 and Figure 2 there were differences in the relative 
abundance of the bacterial species tested in the control. High abundant species which is reflected 
by a low CT value were seen for: Pi, Fn, Sg, Sa, Va, and Ss. Whereas bacterial species Pg, La, 
Aa, Td, and Sm displayed a decreased abundance which is reflected by a higher CT value.  
 
From Table 1 and Figure 2 there were statistical significant differences for Pi (P<.001), Fn 
(P<.001),  Va (P<.001), La (P<.001) and Aa (P<.001). For the 3 treatment groups, there are 3 
paired comparisons—2 with the control and 1 for amixicile vs metronidazole. A difference is 
declared if the p-value for the comparison is less than 0.05/3—a correction for multiple 
comparisons. In the table, if the active antimicrobial is significantly different from the control, 
then the active antimicrobial is labeled with a “-c” and if amixicile is different than 
metronidazole then each antimicrobial is labeled with “-x”. From Table 1 and Figure 2 it 
demonstrates a difference from the control and amixicile in the following bacterial species: Pg, 
Pi, Fn, Sg, Va, La, Aa, and Td. A difference was seen from the control and metronidazole in the 
  
 
following bacterial species: Pi, Fn, Sa, Va, La and Td. Lastly between amixicile and 
metronidazole, differences were observed for bacterial primers Pi and Va.  
 
This information suggests that amixicile is affecting specific bacterial species within the 
microbiome, and is performing with similar efficacy to metronidazole in regards to targeting 
anaerobic bacteria. It also appears that when specific anaerobic bacteria were decreased after 
drug administration, specifically Pi, Fn, and Va, there was an increase in the abundance of 
aerobic species in the microbiome: La and Aa. A possible explanation for this trend could be that 
as selective bacteria species are eliminated from the microbiome is allows for growth of aerobic 
bacteria to obtain that niche. It could also be explained by the fact that all of the bacteria within 
the microbiome have varying growth rates, and therefore certain bacterial species appear to be in 
higher abundance versus other bacterial species. 
  
The results for comparing each of the antimicrobials, separately within each bacterial species is 
shown in Appendix A Table 17 and these differences may be transformed into a fold-change by 
taking the differences with controls and exponentiating the difference. Exponentiating the 95% 
confidence intervals on the differences yields the 95% CI estimate for the fold estimate (and so, 
the CI’s are not symmetric around the fold estimate).  Table 2 and Figure 3 display the fold 
changes observed for all of the Non-PMA runs combined. Statistically significant reductions 
were seen for Pi (<.001), Fn (<.001), and Va (<.001). While a statistically significant increase 
was seen in La (<.001).  The fold change decrease observed for both treatment groups on Pi, Fn 
and Va was similar and displays that both drugs treatment groups target select specific PFOR 
  
 
containing bacteria. The fold change decrease seen in amixicile demonstrates that it is 
performing in the same manner as metronidazole. 
 
Table 1. Corrected CT mean estimates for non-PMA Runs 
Antimicrobials Estimate
Pg (P=.015) Control 31.27 30.59 31.95
Amixicile-c 29.90 29.22 30.58
Metronidazole 30.21 29.52 30.89
Pi (P<.001) Control 17.51 16.83 18.20
Amixicile-cx 24.33 23.65 25.01
Metronidazole-cx 25.89 25.21 26.57
Fn (P<.001) Control 23.38 22.69 24.06
Amixicile-c 25.14 24.45 25.82
Metronidazole-c 25.87 25.19 26.56
Sg (P=.005) Control 18.23 17.55 18.91
Amixicile-c 16.65 15.97 17.33
Metronidazole 17.09 16.40 17.77
Sa (P=.006) Control 16.65 15.97 17.34
Amixicile 15.74 15.06 16.42
Metronidazole-c 15.08 14.39 15.76
Va (P<.001) Control 14.61 13.93 15.29
Amixicile-cx 22.53 21.84 23.21
Metronidazole-cx 24.27 23.59 24.95
La (P<.001) Control 30.12 29.44 30.80
Amixicile-c 27.26 26.58 27.94
Metronidazole-c 28.05 27.36 28.73
Aa (P<.001) Control 32.58 31.90 33.26
Amixicile-c 30.73 30.05 31.42
Metronidazole 31.51 30.83 32.19
Td (P=.001) Control 28.61 27.92 29.29
Amixicile-c 26.92 26.24 27.61
Metronidazole-c 27.22 26.54 27.91
Sm (P=.848) Control 30.82 30.14 31.50
Amixicile 31.03 30.34 31.71
Metronidazole 31.09 30.40 31.77
Ss (P=.032) Control 15.14 14.46 15.82
Amixicile 14.03 13.34 14.71
Metronidazole 14.02 13.34 14.70
95% CI
Corrected CTBacterial 
species
 
 
  
Figure 2. Corrected CT mean estimates for non-PMA Runs 
Figure 2 includes the average CT values taken from samples from four biological replicates (microbiomes prepared on different days) 
each run in triplicate (n=12) under non-PMA conditions. ANOVA analysis was performed and applied to compare the control group to 
amixicile, control group to metronidazole and lastly compare amixicile and metronidazole. A “c” represents a statistically significant 
difference from control and antimicrobial. An “x” represents a statistically significant difference from amixicile and metronidazole.
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 Table 2. Fold change for non-PMA Runs 
Antimicrobials Estimate
Pg Amixicile (P=.006) 2.580 1.322 5.035
Metronidazole (P=.031) 2.087 1.069 4.073
Pi Amixicile (P<.001) 0.009 0.005 0.017
Metronidazole (P<.001) 0.003 0.002 0.006
Fn Amixicile (P<.001) 0.295 0.151 0.576
Metronidazole (P<.001) 0.177 0.091 0.346
Sg Amixicile (P=.001) 2.982 1.528 5.821
Metronidazole (P=.020) 2.209 1.132 4.311
Sa Amixicile (P=.063) 1.887 0.967 3.684
Metronidazole (P=.001) 2.988 1.531 5.832
Va Amixicile (P<.001) 0.004 0.002 0.008
Metronidazole (P<.001) 0.001 0.001 0.002
La Amixicile (P<.001) 7.263 3.721 14.175
Metronidazole (P<.001) 4.220 2.162 8.235
Aa Amixicile (P<.001) 3.592 1.841 7.011
Metronidazole (P=.030) 2.103 1.077 4.104
Td Amixicile (P<.001) 3.209 1.644 6.263
Metronidazole (P=.005) 2.604 1.334 5.081
Sm Amixicile (P=.673) 0.866 0.444 1.691
Metronidazole (P=.585) 0.831 0.426 1.621
Ss Amixicile (P=.024) 2.168 1.111 4.232
Metronidazole (P=.023) 2.178 1.116 4.251
95% CI
FoldBacterial 
species
 
  
Figure 3. Fold change for non-PMA Runs (95% CI) 
Figure 3 represents the fold change observed in bacterial species after treatment of either Amixicile or Metronidazole taken from 
samples from four biological replicates (microbiomes prepared on different days) each run in triplicate (n=12) under non-PMA 
conditions. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and antimicrobial 
treatment.
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Four non-PMA Runs
 Levels of Live Bacteria within Sample : (PMA) Runs 
The three individual PMA runs were also analyzed as one combined experiment. The same data 
processing and analysis were performed on the aggregated non-PMA data was also performed on 
the aggregated PMA data. The average corrected CT estimates are shown in Table 3 and Figure 
4. Similar trends were observed in regards to the abundance levels seen in the non-PMA data, 
and certain bacteria were present in high abundance relative to others. Higher abundant species 
represented by a low control CT value included Pi, Fn, Sg, Sa, Va, and Ss. Whereas a higher CT 
control value reflected lower abundant species and included Pg, La, Aa, Td and Sm.  
 
Statistical significant differences were observed for Pi (P<.001), Fn (P<.001), Va (<.001) and La 
(P<.001). Within the three treatment groups, there are 3 paired comparisons—2 with the control 
and 1 for amixicile vs metronidazole. From Table 2 it demonstrates a difference from the control 
and amxicile in the following bacterial species: Pi, Fn, Sg, Va, La, and Td. A difference was seen 
from the control and metronidazole in the following bacterial species: Pi, Fn, Va, La and Sm. 
Lastly between amixicile and metronidazole, a difference was observed for Td species.  
 The results for comparing each of the antimicrobials, separately within each 
bacterial species is shown in Appendix A PMA Runs 
Table 27. And these differences may be transformed into a fold-change by taking the differences 
with controls and exponentiating the difference. Exponentiating the 95% confidence intervals on 
the differences yields the 95% CI estimate for the fold estimate (and so, the CI’s are not 
symmetric around the fold estimate). Table 4 and Figure 5 display the fold changes observed, 
and overall statistical significant reduction in both the amixicile and metronidazole treated 
groups in Pi, Fn and lastly Va. In the metronidazole group, a statistical significant increase in La 
  
 
species was observed, however this was not significant for the amixicile treated group. Based on 
the similarity of the fold change decreases observed between the two treatment groups, both 
amixicile and metronidazole targeted specific PFOR bacteria within a microbiome and reduced 
their overall numbers following treatment. 
 
Table 3. Corrected CT mean estimates for PMA Runs 
Antimicrobials Estimate
Pg (P=.924) Control 33.06 31.91 34.21
Amixicile 33.42 32.02 34.83
Metronidazole 33.15 31.89 34.41
Pi (P<.001) Control 18.04 16.89 19.19
Amixicile-c 25.67 24.52 26.82
Metronidazole-c 26.94 25.79 28.09
Fn (P<.001) Control 24.32 23.17 25.47
Amixicile-c 28.01 26.86 29.16
Metronidazole-c 27.81 26.66 28.96
Sg (P=.010) Control 19.92 18.77 21.07
Amixicile-c 17.39 16.24 18.54
Metronidazole 18.85 17.71 20.00
Sa (P=.160) Control 18.05 16.90 19.20
Amixicile 16.84 15.69 17.99
Metronidazole 16.57 15.42 17.72
Va (P<.001) Control 15.41 14.27 16.56
Amixicile-c 23.94 22.79 25.09
Metronidazole-c 25.31 24.16 26.46
La (P<.001) Control 31.31 30.16 32.46
Amixicile-c 28.93 27.78 30.08
Metronidazole-c 28.10 26.95 29.25
Aa (P=.268) Control 32.49 31.34 33.64
Amixicile 31.90 30.75 33.05
Metronidazole 31.15 30.00 32.30
Td (P=.011) Control 29.71 28.56 30.86
Amixicile-cx 31.80 30.65 32.95
Metronidazole-x 29.57 28.42 30.72
Sm (P=.011) Control 34.30 33.15 35.45
Amixicile 33.51 32.36 34.66
Metronidazole-c 31.83 30.68 32.98
Ss (P=.045) Control 16.87 15.72 18.02
Amixicile 15.09 13.94 16.24
Metronidazole 15.07 13.92 16.21
95% CI
Corrected CTBacterial 
species
 
  
Figure 4. Corrected CT mean estimates for PMA Runs (95% CIs) 
Figure 4 includes the average CT values taken from samples from three biological replicates (microbiomes prepared on different days) 
each run in triplicate (n=9) under PMA conditions. ANOVA analysis was performed and applied to compare the control group to 
amixicile, control group to metronidazole and lastly compare amixicile and metronidazole. A “c” represents a statistically significant 
difference from control and antimicrobial. An “x” represents a statistically significant difference from amixicile and metronidazole.
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 Table 4. Fold estimates for PMA Runs 
Antimicrobials Estimate
Pg Amixicile (P=.696) 0.779 0.221 2.741
Metronidazole (P=.918) 0.940 0.289 3.062
Pi Amixicile (P<.001) 0.005 0.002 0.016
Metronidazole (P<.001) 0.002 0.001 0.006
Fn Amixicile (P<.001) 0.077 0.025 0.239
Metronidazole (P<.001) 0.089 0.029 0.274
Sg Amixicile (P=.002) 5.778 1.873 17.827
Metronidazole (P=.197) 2.093 0.678 6.456
Sa Amixicile (P=.141) 2.324 0.753 7.170
Metronidazole (P=.073) 2.802 0.908 8.645
Va Amixicile (P<.001) 0.003 0.001 0.008
Metronidazole (P<.001) 0.001 0.000 0.003
La Amixicile (P=.004) 5.196 1.684 16.029
Metronidazole (P<.001) 9.267 3.004 28.589
Aa Amixicile (P=.479) 1.499 0.486 4.624
Metronidazole (P=.106) 2.527 0.819 7.796
Td Amixicile (P=.012) 0.234 0.076 0.723
Metronidazole (P=.869) 1.099 0.356 3.389
Sm Amixicile (P=.338) 1.730 0.561 5.336
Metronidazole (P=.003) 5.520 1.789 17.030
Ss Amixicile (P=.032) 3.445 1.117 10.628
Metronidazole (P=.030) 3.498 1.134 10.792
95% CI
FoldBacterial 
species
 
  
Figure 5. Fold estimates for PMA Runs (95% CIs) 
Figure 5 represents the fold change observed in bacterial species after treatment of either Amixicile or Metronidazole taken from 
samples from three biological replicates (microbiomes prepared on different days) each run in triplicate (n=9) under PMA conditions. 
A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and antimicrobial treatment.
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Comparison of levels of live and dead bacteria within microbiome 
Our analysis involved examination of the extent of inhibition of bacterial growth by two 
antimicrobials: Amixicile and Metronidazole. Such inhibition could have been underestimated if 
the bacteria were metabolically inactive (and thus were dying) making the determination of the 
antimicrobial activity impossible. Thus we also determined the viability of the bacteria within the 
microbiomes by comparing samples analyzed in the presence and absence of propidium 
monoazide (PMA). PMA is a membrane-impermeant dye that selectively penetrates cells with 
compromised membranes, which can be considered dead. PMA was used prior to qPCR to rule 
out any outliers in the data. When PMA is used it will bind to any non-viable cells, and thereby 
prevent binding the DNA primers used. This allows for the analysis to only reflect the total 
living bacteria within the microbiome after antimicrobial treatment.  
 
Based off the data, it appeared that the application of PMA to the DNA eliminated statistical 
changes that were observed in bacterial species La, Aa, and Td in the non-treated PMA qPCR. 
The reason for increased number of statistical significant differences seen in the non-PMA qPCR 
runs could be the result of the primers binding to dead bacteria in the microbiome. Addition of 
the PMA reagent eliminates this possible error by allowing the primers to only bind to live 
bacteria present in the microbiome, which allows for the data to more accurately reflect the live 
state of the microbiome and how the drugs affects bacteria. Both Non-PMA and PMA treated 
groups shared statistically significant reductions in the following bacterial species: Pi (P<.001), 
Fn (P<.001), and Va (<.001). All of these bacteria are PFOR containing bacteria. Therefore 
  
 
within our experiment, it appeared that the application of the PMA aided in determination of the 
effect amixicile and metronidazole had on the oral microbiomes.
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DISCUSSION 
Periodontitis is a complex poly microbial infection that has been associated with gram negative 
bacteria such as Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella 
intermedia and Fusobacterium nucleatum [6, 27]. Unlike acute infections that are typically 
caused by exogenous bacterial agents, periodontitis is a complex chronic infection characterized 
by endogenous oral microorganisms [16, 27]. Oral micro-biofilms enable bacteria to live in a 
layered ecosystem that involves adherence to a solid surface (the tooth) and is surrounded by a 
microbial polysaccharide and protein matrix [16, 27, 43]. This complex eco-system provides 
numerous protective advantages to the bacteria including: nutrient availability and uptake, 
removal of potentially harmful metabolic products, and the development of an appropriate 
chemical ecosystem necessary for the bacteria to survive [27]. It has been shown that there are 
specific associations among bacteria living in dental biofilms [6]. Socransky identified six 
groups of oral bacterial species and grouped them according their spatial relationships which 
include; yellow, green, purple, orange and red complexes [6]. These complexes represent a group 
of distinct bacterial species that tend to aggregate together and contribute to the collective 
survival of the complex within the micro-biofilm. Complexes green and purple act as early 
colonizers, and have the ability to attach directly to the tooth. Orange and red complexes tend to 
be associated with pathogenic bacteria that cause periodontal destruction [6]. 
 
As a result, biofilms are often difficult therapeutic targets because they are dynamic 
communities. The structure of the biofilm allows bacterial species to be more resistant to 
antibiotics and the immune system than planktonic bacteria [27, 43]. Furthermore, there is a 
difference in the types of bacteria that are found in supragingival and subgingival plaque. 
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Supragingival plaque is characterized by Gram + cocci, whereas subgingival plaque is 
characterized by a zone of Gram – spirochetes [27, 48]. Traditionally, periodontitis is first 
managed with mechanical therapy aimed at reducing the overall quantity of bacteria and 
implementing better oral hygiene practices to the patient [7]. Numerous studies have confirmed 
the benefits of mechanical therapy in the treatment of periodontal disease such as decrease in 
probing depths, detoxification of root surfaces and clinical attachment gain following 
implementation of mechanical therapy [7, 29-32]. Despite its effectiveness, mechanical therapy 
is unable to remove all pathogens associated with disease. The trend observed in clinical practice 
is that as disease severity increases the odds of effective removal decrease [8-10]. Additionally 
another factor to consider is the ability for bacterial re-contamination following debridement 
[14,31]. Research indicates that is takes as little as 42 days for the sub-gingival microflora to re-
establish [14,31]. Therefore strict maintenance schedules are required for all patients presenting 
with periodontal disease [33-35]. 
 
Since periodontal diseases are chronic polymicrobial infections, the use of antibiotics has been 
advocated to aid in the reduction of disease causing bacteria. Antibiotics target specific microbes 
and kill them through either a bactericidal or bacteriostatic mechanism. In order for an antibiotic 
to be effective it must be able to reach and penetrate the pathogens [37-39]. When observing in 
vivo micro-biofilms, the available amount of the antibiotic that is able to reach and have effects 
on the bacteria is reduced due to the complex structure of the biofilm [37-39]. Research has 
demonstrated a 100 to 1,000 fold increase in antimicrobial tolerance in biofilms compared to 
planktonic cells [37]. Several mechanisms have been proposed to explain the drug resistance of a 
biofilm and can be classified into 3 groups: intrinsic, mutational and acquired [37,43]. Rams 
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published a study in 2014 to determine the occurrence of in vitro antibiotic resistance among 
selected periodontal patients cultured from patients with chronic periodontitis [20]. Researchers 
found that of all the antibiotics investigated which included; amoxicillin, metronidazole, 
doxycycline, clindamycin, and combination drug therapy; no single antibiotic or combination of 
antibiotics evaluated demonstrated in vitro inhibition of all the assessed periodontal pathogens 
[20].  
 
Taking resistance into consideration, the American Academy of Periodontology wrote a position 
paper advocating for microbiological testing prior to administration of antibiotic therapy [17]. 
Microbiological testing has been confirmed to aid in the diagnosis of periodontal disease activity 
and severity [53, 54]. In clinical practice, microbiological testing is seldom implemented, as the 
majority of periodontal diseases respond positively to mechanical therapy. However, new 
developments in microbiological testing have made it simple, and cost effective to utilize in 
clinical practice [53]. Advancements in microbiological testing enable clinicians to be able to use 
whole saliva in order to determine bacterial species present [53]. A group of researchers found 
that that whole saliva is superior to pooled periodontal pocket samples to detect P. gingivalis, P. 
intermedia, P. nigrescens, and T. denticola in the oral cavity [54]. From our data, we can see that 
specific periodontal pathogens, specifically; P. intermedia, T. denticola  and Veillonella atypica; 
were present in sub-gingival plaque samples harvested from patient with severe chronic 
periodontitis.  Determining the types of bacterial species present in the biofilm is critical as it 
enables the clinician to determine the appropriate antimicrobial to use so that specific pathogens 
can be targeted. 
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At this point in time there is insufficient evidence to advocate for the sole use of antibiotics as 
mono-therapies in the treatment of periodontal diseases [50-52]. Another branch of research 
concerning periodontal disease and antibiotics is the use of antibiotics as adjunctive therapy to 
mechanical therapy. Systematic reviews have displayed conflicting evidence in regards to 
observed additional benefits when using antibiotics as an adjunctive therapy [50-52]. It appears 
that the administration of systemic antibiotics has certain effects on the sub-gingival microbiota, 
but usually does not completely eliminate all of the disease causing bacteria [17,50-52]. In 2002 
Herrera et al published findings to support the use of antimicrobials in specific clinical situations 
such as patients with deep pockets, patients with active disease, or patients with specific 
microbiologic profiles [50]. Whereas in another systematic review published in 2003, Haffajee et 
al concluded that while it appears a benefit exists when antibiotics are added as an adjunctive 
therapy, there is insufficient data to define an optimal antibiotic protocol [51]. From these 
systematic reviews, the American Academy of Periodontology outlined their recommendations 
for antibiotic use that included: aggressive cases of periodontal disease, refractory periodontitis 
and immune compromised patients [17, 40, 41]. Furthermore, the evidence seems to support that 
the quality of mechanical debridement and the time of the prescription of the drug may influence 
the clinical outcome [52]. The greatest benefit seen with antibiotics is post thorough meticulous 
mechanical debridement. Additionally the debridement should be completed within a short 
window (preferable <1 week) under antibiotic prophylaxis in order for the greatest clinical 
benefit to be achieved [52].  
 
Metronidazole, an antibiotic compound, has been used and studied extensively in the treatment 
of various anaerobic infections [45]. It is considered the gold standard, and has been shown to be 
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effective in reducing the periodontal pathogens associated with disease [39, 46, 47]. It is 
considered to be a pro-drug as it requires metabolic activation by sensitive organisms, and 
ultimately interferes with bacterial nucleic acid synthesis [39]. Metronidazole has been used as 
an adjunct to scaling and root planning. When compared to a placebo, the administration of 
metronidazole in conjunction with mechanical therapy had a significant improvement in 
periodontal parameters [46, 47]. Researchers observed that after 6.4 years of follow up, the 
surgical needs were reduced when metronidazole was dispensed in conjunction with mechanical 
debridement after the first and second annual examinations [46, 47]. Despite its ability to target 
strict anaerobes associated with disease, metronidazole undoubtedly has unwelcome side effects 
that include: nausea, gastrointestinal disturbances, disulfram reaction, and neuropathies [39]. Due 
to these unwanted side effects this can lead to issues regarding patient compliance. Therefore the 
decision to utilize an antibiotic must be thoroughly and carefully considered for each patient. 
 
Amixicile is a novel antimicrobial and like metronidazole, it targets specific anaerobic bacteria. 
However amixicile targets and affects the main metabolic pathway strict anaerobes use for 
energy [22-25]. It selectively affects the pyruvate:ferredoxin oxidoreductase (PFOR) pathway. 
PFOR catalyzes the conversion of pyruvate and Coenzyme A (CoA) to CO2 and Acetyl-CoA and 
is an important component of many metabolic pathways found in anaerobic bacteria and 
parasites [22-25]. Animal research models have evaluated the effects when administering 
systemic amixicile in the treatment of a Clostriudum difficile infection and compared it to 
traditional Vancomycin. Researchers found amixicile was efficacious in eradicating the disease, 
but also displayed low toxicity, excellent drug metabolism, and an absence of mutation-based 
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drug resistance [25]. They concluded that amixicile could be a potential new drug to be used in 
infections caused by PFOR-expressing bacteria [22-25]. 
 
Our study aimed to evaluate how an oral microbiome cultured from patients with periodontal 
disease would respond to amixicile. To our knowledge this is the first study to investigate the 
effects of amixicile on an oral in vitro microbiome. Researching a microbiome cultured from 
patient’s disease is lab intensive however it is more clinically relevant than solely looking at 
single species cultures. Our methodology confirmed that a microbiome could be grown 
successfully under anaerobic conditions, and that the microbiomes contained both Gram + and 
Gram – bacteria, which are both present in periodontal disease.  
 
Our hypothesis was that amixicile would selectively target anaerobic bacteria, and reduce their 
prevalence in the microbiome derived from patients with chronic periodontitis.  Secondly, we 
hypothesized that when compared to metronidazole, amixicile would act with similar efficacy in 
reducing the quantities of anaerobic bacteria. Based on the data, it appears that an effect was seen 
when amixicile was applied to a cultured oral microbiome. A statistically significant (P<.001) 
reduction was seen in selective quantities of bacterial species, which included: P. intermedia,  F. 
nucleatum  and V. atypica. All of these bacterial species utilize the PFOR pathway. When the 
data was evaluated to determine fold changes that occurred in the given bacterial species, both 
amixicile and metronidazole displayed a statistically significant (P<.001) decrease in the relative 
quantities of P. intermedia,  F. nucleatum and V. atypica.  
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The data supports the notion that amixicile targets specific anaerobic bacteria within an oral 
microbiome and performs with a similar degree of efficacy to metronidazole. All of the species 
that were affected have been implicated in the development and progression of periodontal 
disease [6]. Fusobacterium nucleatum is a microbe associated with initiation of the microbial 
shift from a primarily gram + to gram – biofilm [16].  This microbial shift is crucial in the 
development of periodontal disease, and the clinical attachment loss that follows. In vitro 
analysis has confirmed that F. nucleatum coaggregates with all of the following bacteria: P. 
gingivalis, Treponema denticola, A. actinomycetemcomitans, P. intermedia, Eubacterium 
species, Selenomonas species and Actinomyces species [44]. In theory, if F.nucleatum could be 
targeted at an earlier stage, it could prevent the transition for a gram + to gram – micro-biofilm. 
This could potentially reduce the harmful effects the micro-biofilm causes in periodontal disease.  
 
The results from this study advocate for further research to be performed regarding the use of 
amixicile as a potential new antimicrobial in the treatment of periodontal disease. While this 
study is only in vitro, it demonstrates that amixicile targets strict anaerobes and reduces their 
quantity. While antibiotics have forever changed the practice of medicine, the issues with 
increasing drug resistance cannot be ignored. Within oral biofilms, resistance to amoxicillin, 
tetracyclines, and metronidazole has been reported [16-18, 20,21,28,38]. Due to the effect that 
amixicile targets a highly conserved pathway within anaerobes, conceptually it supports the idea 
that it will lend to increased drug resistance in the bacteria.  
 
The potential use of amixicile as an adjunct to mechanical therapy is very exciting. When patient 
present with severe periodontal disease, managing deep periodontal pockets and attachment loss 
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is difficult. Furthermore, clinicians anticipate that mechanical therapy will not remove all 
pathogens within the periodontal pocket. As the Academy of Periodontology outlines, antibiotic 
therapy needs to be considered for patients presenting with severe disease. Ideally, thorough 
mechanical debridement should be performed and subsequent re-evaluation should occur. If little 
improvements are seen in control of inflammation with mechanical therapy, then microbiological 
testing should be performed on the patient to determine the types of bacteria present. When sites 
display bleeding and deep probing depths, they have been associated with specific periodontal 
pathogens including P.gingivalis, A. actinomycetemcomitans, and Fusobacterium species [44]. 
As most bacteria associated with severe periodontal disease belong to anaerobic phyla, amixicile 
could provide additional benefits to patients and possibly reduce the need for surgical therapy in 
the future. 
 
Limitations to this research include a lack of effect seen with P.gingivalis.  P.gingivalis did not 
respond to either amixicile or metronidazole treatment. P.gingivalis has been regarded as a 
“keystone pathogen” and its presence has been linked with  active disease in periodontal pockets 
[55]. Ideally amixicile and metronidazole should both have an effect on P.gingivalis because 
P.gingivalis is a gram – anaerobe. However little change was observed from the control and the 
antimicrobial treatment groups. Multiple factors could explain this finding. First, P.gingivalis is a 
sensitive anaerobe to grow in laboratory conditions. Its overall quantity in a biofilm is typically 
smaller when compared to other bacterial species and which was reflected by the higher CT 
values. The high CT value would indicate a lower overall quantity of DNA present in the 
microbiome. Furthermore issues with the primers and their ability to bind to the wild type 
P.gingivalis cultured could also explain the low CT values.  
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Another limitation is the difficulty culturing and growing live complex microbiomes under 
laboratory conditions. As a result, the effect of the host environment was not investigated in this 
study. Furthermore only 12 bacterial species primers were tested in this in vitro microbiome. 
Obviously it is impossible to culture all of the bacteria under laboratory conditions, as over 700 
species exist. Culturing oral plaque is technique sensitive, which is why samples were pooled 
from multiple patients, and multiple qPCR runs were performed and grouped together.  
 
Future research involving Amixicile should focus on the effects it would have on induced 
periodontal disease, and other anaerobic infections in animal models. The systemic side effects, 
optimal dosing, and overall effect on periodontal disease remain to be determined with future 
research. Ultimately randomized clinical trials in human subjects would be needed in order to 
allow Amixicile to be FDA approved in the treatment of periodontal disease, and possibly other 
diseases that are the result of anaerobic dominated infections.  
  
45 
 
 
 
CONCLUSIONS 
 
Amixicile is a promising new antimicrobial in the treatment of anaerobic bacterial infections. 
The effect of amixicile and metronidazole was dependent on the bacteria being analyzed. 
Amixicile and metronidazole had an effect on PFOR-containing bacteria, specifically changes 
were seen for P. intermedia, F. nucleatum  and V. atypical. When comparing amixicile to 
metronidazole, amixicile performed with similar efficacy with the largest effect seen for PFOR 
bacteria. The data supports the notion that amixicile targets specific anaerobic bacteria within an 
oral microbiome cultured from patients with chronic periodontitis and performs with a similar 
degree of efficacy to metronidazole. Such a specific, non-toxic and bioavailable antimicrobial 
would be highly desirable for the treatment of periodontal disease. 
 
The authors confirm that there are no known conflicts of interest associated with this publication 
and there has been no significant financial support for this work that could have influenced its 
outcome. 
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Appendices 
Amixicile targets specific anaerobic bacteria that utilize the pyruvate-ferredoxin 
oxidoreductase pathway (PFOR) 
 
 
 
Figure 6. This figure displays how amixicile targets specific anaerobic bacteria by blocking the 
PFOR metabolic pathway.  
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Guidelines for the diagnosis of periodontitis according to the American Academy of 
Periodontology 2015 
 
Figure 7. Classification of Periodontal Disease Severity
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Run 2017-02-28_144220 
Table 5. Corrected CT mean estimates for Run 2017-02-28_144220 
Bacterial  Corrected CT 
Species Antimicrobial Estimate 95% CI 
Pg (P=.065) Control 32.88 31.98 33.78
Amixicile 31.49 30.59 32.39
Metronidazole 31.66 30.76 32.55
Pi (P<.001) Control 18.95 18.05 19.84
Amixicile-c 26.80 25.90 27.69
Metronidazole-c 28.31 27.41 29.20
Fn (P=.003) Control 24.48 23.58 25.37
Amixicile 25.86 24.96 26.76
Metronidazole-c 26.81 25.91 27.71
Sg (P<.001) Control 20.01 19.11 20.90
Amixicile-c 17.76 16.86 18.66
Metronidazole-c 17.48 16.58 18.37
Sa (P=.026) Control 18.41 17.52 19.31
Amixicile 17.24 16.34 18.13
Metronidazole-c 16.66 15.76 17.55
Va (P<.001) Control 16.52 15.63 17.42
Amixicile-cx 24.52 23.62 25.41
Metronidazole-cx 26.41 25.51 27.30
La (P<.001) Control 32.41 31.52 33.31
Amixicile-c 29.84 28.94 30.73
Metronidazole-c 30.43 29.54 31.33
Aa (P=.002) Control 34.94 34.04 35.83
Amixicile-c 32.69 31.80 33.59
Metronidazole-c 32.87 31.97 33.77
Td (P<.001) Control 32.48 31.59 33.38
Amixicile-c 28.94 28.04 29.84
Metronidazole-c 28.96 28.07 29.86
Sm (P=.252) Control 32.60 31.71 33.50
Amixicile 32.86 31.97 33.76
Metronidazole 31.85 30.95 32.75
Ss (P=.283) Control 16.55 15.65 17.44
Amixicile 15.89 14.99 16.79
  Metronidazole 15.56 14.66 16.45
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Figure 8. Corrected CT mean estimates for Run 2017-02-28_144220 (95% CIs) 
Figure 6 represents the average CT values taken of Run 2017-02-28_144220. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” represents a statisitically significant difference 
from Amxicile and Metronidazole 
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Table 6. Differences in the Corrected CT mean estimates for Run 2017-02_28_144220  
Bacterial  Corrected CT 
Species Compare Estimate 95% CI 
Pg CvA (P=.033) 1.391 0.124 2.658
CvM (P=.058) 1.223 -0.044 2.491
AvM (P=.789) -0.168 -1.435 1.100
Pi CvA (P<.001) -7.850 -9.118 -6.583
CvM (P<.001) -9.359 -10.626 -8.091
AvM (P=.021) -1.509 -2.776 -0.241
Fn CvA (P=.034) -1.383 -2.650 -0.115
CvM (P<.001) -2.332 -3.599 -1.064
AvM (P=.137) -0.949 -2.216 0.318
Sg CvA (P=.001) 2.248 0.981 3.516
CvM (P<.001) 2.530 1.263 3.798
AvM (P=.653) 0.282 -0.985 1.549
Sa CvA (P=.068) 1.175 -0.092 2.442
CvM (P=.008) 1.756 0.488 3.023
AvM (P=.357) 0.581 -0.687 1.848
Va CvA (P<.001) -7.992 -9.259 -6.724
CvM (P<.001) -9.882 -11.149 -8.614
AvM (P=.005) -1.890 -3.158 -0.623
La CvA (P<.001) 2.574 1.307 3.842
CvM (P=.003) 1.980 0.713 3.247
AvM (P=.346) -0.594 -1.862 0.673
Aa CvA (P=.001) 2.242 0.974 3.509
CvM (P=.002) 2.066 0.799 3.334
AvM (P=.779) -0.176 -1.443 1.092
Td CvA (P<.001) 3.542 2.274 4.809
CvM (P<.001) 3.519 2.252 4.787
AvM (P=.971) -0.023 -1.290 1.245
Sm CvA (P=.676) -0.262 -1.529 1.005
CvM (P=.234) 0.753 -0.514 2.020
AvM (P=.112) 1.015 -0.252 2.282
Ss CvA (P=.298) 0.658 -0.610 1.925
CvM (P=.122) 0.989 -0.279 2.256
  AvM (P=.598) 0.331 -0.936 1.598
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Figure 9. Differences in the Corrected CT mean estimates for Run 2017-02_28_144220 (95% CIs) 
Figure 7 represents the differences in corrected CT mean estimates from the original CT values  prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Table 7. Fold estimates for Run 2017-02-28_144220 
Bacterial  Fold 
Species Antimicrobial Estimate 95% CI 
Pg Amixicile (P=.033) 2.623 1.090 6.314
Metronidazole (P=.058) 2.335 0.970 5.621
Pi Amixicile (P<.001) 0.004 0.002 0.010
Metronidazole (P<.001) 0.002 0.001 0.004
Fn Amixicile (P=.034) 0.384 0.159 0.923
Metronidazole (P<.001) 0.199 0.083 0.478
Sg Amixicile (P=.001) 4.751 1.974 11.437
Metronidazole (P<.001) 5.777 2.400 13.906
Sa Amixicile (P=.068) 2.258 0.938 5.435
Metronidazole (P=.008) 3.377 1.403 8.129
Va Amixicile (P<.001) 0.004 0.002 0.009
Metronidazole (P<.001) 0.001 0.000 0.003
La Amixicile (P<.001) 5.955 2.474 14.336
Metronidazole (P=.003) 3.945 1.639 9.496
Aa Amixicile (P=.001) 4.730 1.965 11.386
Metronidazole (P=.002) 4.188 1.740 10.081
Td Amixicile (P<.001) 11.646 4.838 28.035
Metronidazole (P<.001) 11.466 4.763 27.600
Sm Amixicile (P=.676) 0.834 0.346 2.008
Metronidazole (P=.234) 1.685 0.700 4.057
Ss Amixicile (P=.298) 1.578 0.655 3.798
  Metronidazole (P=.122) 1.985 0.824 4.777
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Figure 10. Fold estimates for Run 2017-02_28_144220 (95% CIs) 
Figure 8 represents the fold change observed for Run 2017-2_28_144220 n bacterial species after treatment of either Amixicile or 
Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment 
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Run 2017-03-07_1 
Table 8. Corrected CT mean estimates for Run 2017-03-07_1 
Bacterial species 
Corrected CT 
Antimicrobials Estimate 95% CI 
Pg (P=.004) Control 32.36 31.93 32.79
Amixicile-c 31.30 30.87 31.73
  Metronidazole-c 31.59 31.16 32.02
Pi (P<.001) Control 18.29 17.86 18.72
Amixicile-cx 25.64 25.21 26.07
  Metronidazole-cx 27.19 26.76 27.62
Fn (P<.001) Control 24.70 24.27 25.13
Amixicile-c 30.15 29.73 30.58
  Metronidazole-c 29.70 29.27 30.13
Sg (P<.001) Control 21.37 20.94 21.80
Amixicile-cx 20.48 20.05 20.91
  Metronidazole-x 21.92 21.49 22.35
Sa (P<.001) Control 17.99 17.56 18.42
Amixicile-x 17.28 16.85 17.71
  Metronidazole-cx 16.41 15.98 16.84
Va (P<.001) Control 16.15 15.73 16.58
Amixicile-cx 24.56 24.13 24.99
  Metronidazole-cx 25.53 25.10 25.96
La (P<.001) Control 30.86 30.43 31.29
Amixicile-c 29.16 28.74 29.59
  Metronidazole-c 29.33 28.90 29.76
Aa (P=.002) Control 32.78 32.35 33.21
Amixicile-c 33.95 33.53 34.38
  Metronidazole 33.24 32.81 33.67
Td (P=.235) Control 28.70 28.27 29.13
Amixicile 28.31 27.88 28.74
  Metronidazole 28.21 27.78 28.64
Sm (P<.001) Control 30.64 30.21 31.07
Amixicile-cx 33.15 32.72 33.58
  Metronidazole-x 31.31 30.88 31.74
Ss (P<.001) Control 16.90 16.47 17.33
Amixicile-c 15.77 15.34 16.20
  Metronidazole-c 15.63 15.20 16.06
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Figure 11. Corrected CT mean estimates for Run 2017-03-07_1 (96% CIs) 
Figure 9 represents the average corrected CT values taken of Run 2017-03-07_1. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” represents a statisitically significant difference 
from Amxicile and Metronidazole 
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Table 9. Differences in the Corrected CT mean estimates for Run 2017-03-07_1 
Bacterial species 
Corrected CT 
Compare Estimate 95% CI 
Pg CvA (P=.001) 1.057 0.450 1.664
CvM (P=.015) 0.768 0.161 1.375
AvM (P=.339) -0.289 -0.896 0.318
Pi CvA (P<.001) -7.349 -7.956 -6.741
CvM (P<.001) -8.902 -9.509 -8.295
AvM (P<.001) -1.554 -2.161 -0.946
Fn CvA (P<.001) -5.457 -6.065 -4.850
CvM (P<.001) -4.999 -5.606 -4.391
AvM (P=.133) 0.459 -0.148 1.066
Sg CvA (P=.005) 0.894 0.287 1.501
CvM (P=.078) -0.542 -1.150 0.065
AvM (P<.001) -1.436 -2.044 -0.829
Sa CvA (P=.025) 0.701 0.094 1.309
CvM (P<.001) 1.576 0.969 2.183
AvM (P=.006) 0.874 0.267 1.482
Va CvA (P<.001) -8.405 -9.012 -7.797
CvM (P<.001) -9.377 -9.984 -8.769
AvM (P=.003) -0.972 -1.579 -0.365
La CvA (P<.001) 1.696 1.088 2.303
CvM (P<.001) 1.533 0.925 2.140
AvM (P=.588) -0.163 -0.770 0.444
Aa CvA (P<.001) -1.171 -1.779 -0.564
CvM (P=.135) -0.457 -1.065 0.150
AvM (P=.023) 0.714 0.107 1.321
Td CvA (P=.199) 0.390 -0.217 0.998
CvM (P=.110) 0.490 -0.117 1.097
AvM (P=.740) 0.100 -0.508 0.707
Sm CvA (P<.001) -2.516 -3.124 -1.909
CvM (P=.032) -0.670 -1.277 -0.063
AvM (P<.001) 1.846 1.239 2.454
Ss CvA (P<.001) 1.127 0.520 1.734
CvM (P<.001) 1.267 0.660 1.874
  AvM (P=.641) 0.140 -0.467 0.747
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Figure 12. Differences in the Corrected CT mean estimates for Run 2017-03-07_1 (95% CI) 
Figure 10 represents the differences in corrected CT mean estimates from the original CT values  prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Table 10. Fold change for Run 2017-03-07_1 
Bacterial 
species 
Fold 
Antimicrobials Estimate 95% CI 
Pg Amixicile (P=.001) 2.081 1.366 3.170
Metronidazole (P=.015) 1.703 1.118 2.595
Pi Amixicile (P<.001) 0.006 0.004 0.009
Metronidazole (P<.001) 0.002 0.001 0.003
Fn Amixicile (P<.001) 0.023 0.015 0.035
Metronidazole (P<.001) 0.031 0.021 0.048
Sg Amixicile (P=.005) 1.858 1.220 2.831
Metronidazole (P=.078) 0.687 0.451 1.046
Sa Amixicile (P=.025) 1.626 1.067 2.477
Metronidazole (P<.001) 2.981 1.957 4.541
Va Amixicile (P<.001) 0.003 0.002 0.004
Metronidazole (P<.001) 0.002 0.001 0.002
La Amixicile (P<.001) 3.239 2.126 4.934
Metronidazole (P<.001) 2.893 1.899 4.407
Aa Amixicile (P<.001) 0.444 0.291 0.676
Metronidazole (P=.135) 0.728 0.478 1.110
Td Amixicile (P=.199) 1.311 0.860 1.997
Metronidazole (P=.110) 1.405 0.922 2.140
Sm Amixicile (P<.001) 0.175 0.115 0.266
Metronidazole (P=.032) 0.629 0.413 0.958
Ss Amixicile (P<.001) 2.184 1.434 3.327
  Metronidazole (P<.001) 2.406 1.580 3.666
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Figure 13. Fold change for Run 2017-03-07_1 (95% CIs) 
Figure 11 represents the fold change observed for RUN 2017-03-07_1 in bacterial species after treatment of either Amixicile or 
Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment 
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Run 2017-03-21_162558 
Table 11. Corrected CT mean estimates for Run 2017-03-21_162558 
Antimicrobials Estimate
Pg (P<.001) Control 31.11 30.72 31.51
Amixicile-cx 28.59 28.19 28.98
Metronidazole-cx 29.94 29.54 30.33
Pi (P<.001) Control 17.34 16.95 17.74
Amixicile-cx 23.67 23.27 24.06
Metronidazole-cx 25.89 25.50 26.29
Fn (P<.001) Control 23.29 22.89 23.68
Amixicile-x 23.00 22.60 23.39
Metronidazole-cx 24.92 24.52 25.31
Sg (P<.001) Control 17.11 16.71 17.50
Amixicile-cx 14.59 14.20 14.99
Metronidazole-cx 15.71 15.32 16.11
Sa (P<.001) Control 16.56 16.16 16.96
Amixicile-c 15.64 15.24 16.03
Metronidazole-c 15.28 14.88 15.67
Va (P<.001) Control 14.82 14.42 15.21
Amixicile-cx 21.54 21.15 21.94
Metronidazole-cx 23.99 23.60 24.39
La (P<.001) Control 29.59 29.19 29.99
Amixicile-cx 27.10 26.71 27.50
Metronidazole-cx 27.82 27.42 28.21
Aa (P<.001) Control 32.47 32.08 32.87
Amixicile-cx 29.58 29.18 29.97
Metronidazole-cx 31.36 30.97 31.76
Td (P<.001) Control 27.87 27.48 28.27
Amixicile-cx 26.39 25.99 26.78
Metronidazole-x 27.69 27.30 28.09
Sm (P<.001) Control 29.68 29.28 30.07
Amixicile-cx 30.43 30.03 30.82
Metronidazole-cx 32.01 31.62 32.41
Ss (P<.001) Control 14.90 14.50 15.29
Amixicile-c 13.33 12.93 13.72
Metronidazole-c 13.99 13.60 14.39
95% CI
Corrected CTBacterial 
species
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Figure 14. Corrected CT mean estimates for Run 2017-03-21_162558 (95% CI) 
Figure 12 represents the average corrected CT values taken of Run 2017-03-21_162558. ANOVA analysis was performed and applied 
to compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” represents a statistically significant difference 
from Amixicile and Metronidazole 
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Table 12. Differences in the Corrected CT mean estimates for Run 2017-03-21_162558 
 
 
Compare Estimate
Pg CvA (P<.001) 2.527 1.968 3.087
CvM (P<.001) 1.176 0.616 1.735
AvM (P<.001) -1.352 -1.911 -0.792
Pi CvA (P<.001) -6.324 -6.884 -5.765
CvM (P<.001) -8.549 -9.109 -7.990
AvM (P<.001) -2.225 -2.785 -1.666
Fn CvA (P=.303) 0.287 -0.273 0.846
CvM (P<.001) -1.634 -2.193 -1.074
AvM (P<.001) -1.921 -2.480 -1.361
Sg CvA (P<.001) 2.515 1.955 3.074
CvM (P<.001) 1.395 0.835 1.954
AvM (P<.001) -1.120 -1.679 -0.560
Sa CvA (P=.002) 0.923 0.363 1.482
CvM (P<.001) 1.282 0.722 1.841
AvM (P=.200) 0.359 -0.201 0.918
Va CvA (P<.001) -6.722 -7.281 -6.163
CvM (P<.001) -9.175 -9.735 -8.616
AvM (P<.001) -2.453 -3.013 -1.894
La CvA (P<.001) 2.485 1.926 3.045
CvM (P<.001) 1.773 1.214 2.333
AvM (P=.014) -0.712 -1.271 -0.152
Aa CvA (P<.001) 2.893 2.334 3.452
CvM (P<.001) 1.107 0.547 1.666
AvM (P<.001) -1.786 -2.346 -1.227
Td CvA (P<.001) 1.487 0.928 2.046
CvM (P=.519) 0.179 -0.381 0.738
AvM (P<.001) -1.308 -1.868 -0.749
Sm CvA (P=.010) -0.751 -1.311 -0.192
CvM (P<.001) -2.338 -2.898 -1.779
AvM (P<.001) -1.587 -2.146 -1.027
Ss CvA (P<.001) 1.570 1.010 2.129
CvM (P=.002) 0.904 0.345 1.464
AvM (P=.021) -0.666 -1.225 -0.106
95% CI
Corrected CTBacterial 
species
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Figure 15. Differences in the Corrected CT mean estimates for Run 2017-03-21_162558 
Figure 13 represents the differences in corrected CT mean estimates from the original CT values  prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Table 13. Fold change for Run 2017-03-21_162558 
Antimicrobials Estimate
Pg Amixicile (P<.001) 5.765 3.912 8.496
Metronidazole (P<.001) 2.259 1.533 3.329
Pi Amixicile (P<.001) 0.012 0.008 0.018
Metronidazole (P<.001) 0.003 0.002 0.004
Fn Amixicile (P=.303) 1.220 0.828 1.798
Metronidazole (P<.001) 0.322 0.219 0.475
Sg Amixicile (P<.001) 5.715 3.878 8.422
Metronidazole (P<.001) 2.629 1.784 3.875
Sa Amixicile (P=.002) 1.895 1.286 2.793
Metronidazole (P<.001) 2.431 1.650 3.583
Va Amixicile (P<.001) 0.009 0.006 0.014
Metronidazole (P<.001) 0.002 0.001 0.003
La Amixicile (P<.001) 5.600 3.800 8.253
Metronidazole (P<.001) 3.419 2.320 5.038
Aa Amixicile (P<.001) 7.428 5.040 10.947
Metronidazole (P<.001) 2.154 1.461 3.174
Td Amixicile (P<.001) 2.803 1.902 4.131
Metronidazole (P=.519) 1.132 0.768 1.668
Sm Amixicile (P=.010) 0.594 0.403 0.875
Metronidazole (P<.001) 0.198 0.134 0.291
Ss Amixicile (P<.001) 2.968 2.014 4.375
Metronidazole (P=.002) 1.871 1.270 2.758
95% CI
FoldBacterial 
species
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Figure 16. Fold change for Run 2017-03-21_162558 (95% CI) 
Figure 11 represents the fold change observed for RUN 2017-03-07_1 in bacterial species after treatment of either Amixicile or 
Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment 
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Run 2017-04-13_175325 
Table 14. Corrected CT mean estimates for Run 2017-04-13_175325 
Antimicrobials Estimate
Pg (P=.079) Control 28.72 28.06 29.38
Amixicile 28.23 27.56 28.89
Metronidazole 27.64 26.98 28.30
Pi (P<.001) Control 15.47 14.81 16.14
Amixicile-c 21.22 20.55 21.88
Metronidazole-c 22.17 21.51 22.83
Fn (P=.098) Control 21.04 20.38 21.70
Amixicile 21.53 20.86 22.19
Metronidazole 22.07 21.41 22.73
Sg (P=.048) Control 14.43 13.76 15.09
Amixicile 13.78 13.12 14.44
Metronidazole-c 13.24 12.57 13.90
Sa (P=.003) Control 13.66 13.00 14.32
Amixicile 12.79 12.13 13.46
Metronidazole-c 11.96 11.29 12.62
Va (P<.001) Control 10.93 10.27 11.60
Amixicile-cx 19.49 18.83 20.15
Metronidazole-cx 21.14 20.48 21.80
La (P<.001) Control 27.63 26.96 28.29
Amixicile-cx 22.94 22.28 23.60
Metronidazole-cx 24.60 23.94 25.27
Aa (P<.001) Control 30.13 29.47 30.79
Amixicile-cx 26.71 26.05 27.37
Metronidazole-cx 28.55 27.89 29.22
Td (P=.009) Control 25.37 24.70 26.03
Amixicile-c 24.06 23.39 24.72
Metronidazole-c 24.03 23.37 24.69
Sm (P<.001) Control 30.36 29.70 31.02
Amixicile-cx 27.66 27.00 28.32
Metronidazole-cx 29.18 28.51 29.84
Ss (P=.015) Control 12.23 11.57 12.89
Amixicile 11.12 10.45 11.78
Metronidazole-c 10.90 10.23 11.56
95% CI
Corrected CTBacterial 
species
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Figure 17. Corrected CT mean estimates for Run 2017-04-13_175325 (95% CIs) 
Figure 15 represents the average corrected CT values taken of Run 2017-04-13_175325. ANOVA analysis was performed and applied 
to compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” represents a statistically significant difference 
from Amixicile and Metronidazole 
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Table 15. Differences in the Corrected CT mean estimates for Run 2017-04-13_175325 
 
Compare Estimate
Pg CvA (P=.291) 0.493 -0.444 1.430
CvM (P=.026) 1.079 0.141 2.016
AvM (P=.212) 0.586 -0.352 1.523
Pi CvA (P<.001) -5.744 -6.681 -4.807
CvM (P<.001) -6.696 -7.634 -5.759
AvM (P=.047) -0.952 -1.890 -0.015
Fn CvA (P=.299) -0.485 -1.422 0.452
CvM (P=.033) -1.027 -1.964 -0.090
AvM (P=.247) -0.542 -1.479 0.395
Sg CvA (P=.168) 0.649 -0.288 1.586
CvM (P=.015) 1.190 0.253 2.127
AvM (P=.247) 0.542 -0.396 1.479
Sa CvA (P=.069) 0.867 -0.071 1.804
CvM (P<.001) 1.704 0.767 2.641
AvM (P=.078) 0.837 -0.100 1.774
Va CvA (P<.001) -8.554 -9.492 -7.617
CvM (P<.001) -10.206 -11.143 -9.269
AvM (P=.001) -1.651 -2.589 -0.714
La CvA (P<.001) 4.687 3.750 5.624
CvM (P<.001) 3.022 2.085 3.959
AvM (P=.001) -1.665 -2.602 -0.728
Aa CvA (P<.001) 3.416 2.479 4.354
CvM (P=.002) 1.574 0.637 2.511
AvM (P<.001) -1.843 -2.780 -0.905
Td CvA (P=.008) 1.309 0.372 2.246
CvM (P=.007) 1.334 0.397 2.271
AvM (P=.957) 0.025 -0.912 0.962
Sm CvA (P<.001) 2.702 1.765 3.639
CvM (P=.015) 1.184 0.247 2.121
AvM (P=.002) -1.518 -2.455 -0.581
Ss CvA (P=.022) 1.112 0.174 2.049
CvM (P=.007) 1.333 0.396 2.270
AvM (P=.633) 0.221 -0.716 1.158
95% CI
Corrected CTBacterial 
species
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Figure 18. Differences in the Corrected CT mean estimates for Run 2017-04-13_175325 
Figure 16 represents the differences in corrected CT mean estimates from the original CT values prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Table 16. Fold estimates for Run 2017-04-13_175325 
Antimicrobials Estimate
Pg Amixicile (P=.291) 1.407 0.735 2.695
Metronidazole (P=.026) 2.112 1.103 4.044
Pi Amixicile (P<.001) 0.019 0.010 0.036
Metronidazole (P<.001) 0.010 0.005 0.018
Fn Amixicile (P=.299) 0.715 0.373 1.368
Metronidazole (P=.033) 0.491 0.256 0.940
Sg Amixicile (P=.168) 1.568 0.819 3.002
Metronidazole (P=.015) 2.282 1.192 4.369
Sa Amixicile (P=.069) 1.823 0.952 3.491
Metronidazole (P<.001) 3.258 1.701 6.237
Va Amixicile (P<.001) 0.003 0.001 0.005
Metronidazole (P<.001) 0.001 0.000 0.002
La Amixicile (P<.001) 25.759 13.453 49.321
Metronidazole (P<.001) 8.125 4.243 15.557
Aa Amixicile (P<.001) 10.677 5.577 20.444
Metronidazole (P=.002) 2.977 1.555 5.701
Td Amixicile (P=.008) 2.477 1.294 4.743
Metronidazole (P=.007) 2.521 1.317 4.826
Sm Amixicile (P<.001) 6.508 3.399 12.461
Metronidazole (P=.015) 2.272 1.187 4.350
Ss Amixicile (P=.022) 2.161 1.129 4.137
Metronidazole (P=.007) 2.519 1.315 4.823
95% CI
FoldBacterial 
species
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Figure 19. Fold estimates for Run 2017-04-13_175325 (95% CIs) 
Figure 17 represents the fold change observed for Run 2017-04-13_175325 in bacterial species after treatment of either Amixicile or 
Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment 
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Non-PMA Runs 
Table 17. Differences in the Corrected CT mean estimates for non-PMA Runs 
 
 
Compare Estimate
Pg CvA (P=.006) 1.367 0.402 2.332
CvM (P=.031) 1.061 0.097 2.026
AvM (P=.533) -0.306 -1.270 0.659
Pi CvA (P<.001) -6.817 -7.781 -5.852
CvM (P<.001) -8.377 -9.341 -7.412
AvM (P=.002) -1.560 -2.525 -0.595
Fn CvA (P<.001) -1.759 -2.724 -0.795
CvM (P<.001) -2.498 -3.462 -1.533
AvM (P=.133) -0.738 -1.703 0.226
Sg CvA (P=.001) 1.576 0.612 2.541
CvM (P=.020) 1.143 0.178 2.108
AvM (P=.377) -0.433 -1.398 0.532
Sa CvA (P=.063) 0.916 -0.048 1.881
CvM (P=.001) 1.579 0.614 2.544
AvM (P=.177) 0.663 -0.302 1.628
Va CvA (P<.001) -7.918 -8.883 -6.953
CvM (P<.001) -9.660 -10.625 -8.695
AvM (P<.001) -1.742 -2.706 -0.777
La CvA (P<.001) 2.861 1.896 3.825
CvM (P<.001) 2.077 1.112 3.042
AvM (P=.111) -0.783 -1.748 0.181
Aa CvA (P<.001) 1.845 0.880 2.810
CvM (P=.030) 1.072 0.108 2.037
AvM (P=.116) -0.773 -1.737 0.192
Td CvA (P<.001) 1.682 0.717 2.647
CvM (P=.005) 1.380 0.416 2.345
AvM (P=.538) -0.302 -1.266 0.663
Sm CvA (P=.673) -0.207 -1.172 0.758
CvM (P=.585) -0.268 -1.232 0.697
AvM (P=.901) -0.061 -1.026 0.904
Ss CvA (P=.024) 1.117 0.152 2.081
CvM (P=.023) 1.123 0.158 2.088
AvM (P=.989) 0.007 -0.958 0.971
95% CI
Corrected CTBacterial 
species
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Figure 20. Differences in the Corrected CT mean estimates for non-PMA Runs 
Figure 18 represents the differences in corrected CT mean estimates from the original CT values  prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Run 2017-02-28_pma 
Table 18. Corrected CT mean estimates for Run 2017-02-28_pma 
 
Antimicrobials Estimate
Pg (P=.793) Control 33.23 31.83 34.62
Amixicile 33.86 31.89 35.82
Metronidazole 33.81 32.42 35.21
Pi (P<.001) Control 18.41 17.01 19.80
Amixicile-c 25.90 24.51 27.30
Metronidazole-c 27.20 25.80 28.59
Fn (P=.010) Control 23.15 21.76 24.55
Amixicile 25.19 23.80 26.59
Metronidazole-c 26.29 24.90 27.69
Sg (P=.020) Control 20.00 18.60 21.39
Amixicile-c 17.11 15.71 18.50
Metronidazole 18.69 17.30 20.09
Sa (P=.127) Control 17.54 16.14 18.93
Amixicile 16.26 14.87 17.66
Metronidazole 15.53 14.14 16.93
Va (P<.001) Control 15.93 14.53 17.32
Amixicile-c 23.19 21.80 24.59
Metronidazole-c 24.85 23.45 26.24
La (P=.003) Control 31.85 30.45 33.24
Amixicile-c 28.95 27.55 30.34
Metronidazole-c 28.52 27.12 29.91
Aa (P=.790) Control 31.83 30.44 33.23
Amixicile 32.29 30.90 33.69
Metronidazole 31.64 30.25 33.04
Td (P<.001) Control 30.26 28.87 31.66
Amixicile-cx 33.49 32.10 34.89
Metronidazole-x 29.64 28.24 31.03
Sm (P=.670) Control 34.64 33.25 36.04
Amixicile 33.78 32.38 35.17
Metronidazole 34.17 32.78 35.57
Ss (P=.078) Control 16.64 15.25 18.04
Amixicile 14.59 13.20 15.99
Metronidazole 14.75 13.35 16.14
95% CI
Corrected CTBacterial 
species
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Figure 21. Corrected CT mean estimates for Run 2017-02-28_pma (95% CIs) 
Figure 19 represents the average corrected CT values taken of Run 2017-02-28_pma. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” represents a statistically significant difference 
from Amixicile and Metronidazole 
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Table 19. Differences in the Corrected CT mean estimates for Run 2017-02-28_pma 
 
Compare Estimate
Pg CvA (P=.598) -0.628 -3.038 1.783
CvM (P=.548) -0.586 -2.559 1.386
AvM (P=.972) 0.041 -2.369 2.452
Pi CvA (P<.001) -7.493 -9.466 -5.520
CvM (P<.001) -8.787 -10.760 -6.814
AvM (P=.190) -1.294 -3.267 0.679
Fn CvA (P=.043) -2.039 -4.012 -0.066
CvM (P=.003) -3.140 -5.113 -1.167
AvM (P=.263) -1.100 -3.073 0.873
Sg CvA (P=.006) 2.891 0.919 4.864
CvM (P=.186) 1.306 -0.667 3.279
AvM (P=.111) -1.585 -3.558 0.387
Sa CvA (P=.196) 1.276 -0.697 3.249
CvM (P=.046) 2.006 0.033 3.979
AvM (P=.455) 0.730 -1.242 2.703
Va CvA (P<.001) -7.265 -9.238 -5.292
CvM (P<.001) -8.920 -10.893 -6.947
AvM (P=.097) -1.655 -3.628 0.318
La CvA (P=.005) 2.900 0.927 4.873
CvM (P=.002) 3.331 1.358 5.303
AvM (P=.659) 0.430 -1.542 2.403
Aa CvA (P=.638) -0.458 -2.431 1.515
CvM (P=.846) 0.188 -1.784 2.161
AvM (P=.508) 0.647 -1.326 2.620
Td CvA (P=.002) -3.230 -5.203 -1.257
CvM (P=.523) 0.623 -1.350 2.596
AvM (P<.001) 3.853 1.880 5.826
Sm CvA (P=.376) 0.868 -1.105 2.841
CvM (P=.628) 0.473 -1.500 2.446
AvM (P=.685) -0.395 -2.368 1.578
Ss CvA (P=.043) 2.046 0.073 4.018
CvM (P=.059) 1.894 -0.079 3.867
AvM (P=.876) -0.152 -2.124 1.821
95% CI
Corrected CTBacterial 
species
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Figure 22. Differences in the Corrected CT mean estimates for Run 2017-02-28_pma 
Figure 20 represents the differences in corrected CT mean estimates from the original CT values prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Table 20. Fold estimates for Run 2017-02-28_pma 
 
Antimicrobials Estimate
Pg Amixicile (P=.598) 0.647 0.122 3.441
Metronidazole (P=.548) 0.666 0.170 2.614
Pi Amixicile (P<.001) 0.006 0.001 0.022
Metronidazole (P<.001) 0.002 0.001 0.009
Fn Amixicile (P=.043) 0.243 0.062 0.955
Metronidazole (P=.003) 0.113 0.029 0.445
Sg Amixicile (P=.006) 7.420 1.890 29.126
Metronidazole (P=.186) 2.473 0.630 9.706
Sa Amixicile (P=.196) 2.421 0.617 9.505
Metronidazole (P=.046) 4.017 1.023 15.769
Va Amixicile (P<.001) 0.007 0.002 0.026
Metronidazole (P<.001) 0.002 0.001 0.008
La Amixicile (P=.005) 7.465 1.902 29.302
Metronidazole (P=.002) 10.060 2.563 39.488
Aa Amixicile (P=.638) 0.728 0.185 2.857
Metronidazole (P=.846) 1.140 0.290 4.473
Td Amixicile (P=.002) 0.107 0.027 0.418
Metronidazole (P=.523) 1.540 0.392 6.046
Sm Amixicile (P=.376) 1.825 0.465 7.163
Metronidazole (P=.628) 1.388 0.354 5.448
Ss Amixicile (P=.043) 4.129 1.052 16.206
Metronidazole (P=.059) 3.717 0.947 14.591
95% CI
FoldBacterial 
species
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Figure 23. Fold estimates for Run 2017-02-28_pma (95% CIs) 
Figure 21 represents the fold change observed for Run 2017-02-28_pma in bacterial species after treatment of either Amixicile or 
Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment 
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Run 2017-03-07_pma 
 
Table 21. Corrected CT mean estimates for Run 2017-03-07_pma 
 
Antimicrobials Estimate
Pg (P=.006) Control 32.82 32.18 33.46
Amixicile-x 32.82 32.18 33.45
Metronidazole-cx 31.48 30.84 32.12
Pi (P<.001) Control 18.38 17.74 19.01
Amixicile-c 26.85 26.21 27.49
Metronidazole-c 27.63 26.99 28.27
Fn (P<.001) Control 25.15 24.51 25.79
Amixicile-cx 33.06 32.42 33.69
Metronidazole-cx 29.39 28.76 30.03
Sg (P<.001) Control 21.74 21.10 22.38
Amixicile-cx 19.30 18.66 19.94
Metronidazole-x 21.58 20.94 22.22
Sa (P=.003) Control 20.26 19.63 20.90
Amixicile 19.16 18.52 19.80
Metronidazole-c 18.63 17.99 19.27
Va (P<.001) Control 16.30 15.66 16.94
Amixicile-c 26.01 25.37 26.64
Metronidazole-c 25.65 25.01 26.29
La (P<.001) Control 31.03 30.39 31.67
Amixicile-x 30.56 29.92 31.19
Metronidazole-cx 27.72 27.09 28.36
Aa (P<.001) Control 32.25 31.61 32.88
Amixicile-x 31.28 30.64 31.92
Metronidazole-cx 29.12 28.48 29.76
Td (P<.001) Control 29.77 29.13 30.41
Amixicile-cx 31.97 31.33 32.61
Metronidazole-cx 28.33 27.69 28.97
Sm (P<.001) Control 35.68 35.05 36.32
Amixicile-cx 34.11 33.47 34.74
Metronidazole-cx 29.01 28.37 29.64
Ss (P<.001) Control 18.16 17.52 18.80
Amixicile-c 17.00 16.36 17.64
Metronidazole-c 16.16 15.53 16.80
95% CI
Corrected CTBacterial 
species
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Figure 24. Corrected CT mean estimates for Run 2017-03-07_pma (95% CIs) 
Figure 22 represents the average corrected CT values taken of Run 2017-03-07_pma. ANOVA analysis was performed and applied to 
compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. A “c” 
represents a statistically significant difference from control and antimicrobial. An “x” represents a statistically significant difference 
from Amixicile and Metronidazole 
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Table 22. Differences in the Corrected CT mean estimates for Run 2017-03-07_pma 
 
Compare Estimate
Pg CvA (P=.996) 0.002 -0.901 0.905
CvM (P=.005) 1.337 0.435 2.240
AvM (P=.005) 1.335 0.433 2.238
Pi CvA (P<.001) -8.475 -9.378 -7.573
CvM (P<.001) -9.251 -10.154 -8.349
AvM (P=.089) -0.776 -1.679 0.127
Fn CvA (P<.001) -7.904 -8.807 -7.002
CvM (P<.001) -4.244 -5.146 -3.341
AvM (P<.001) 3.661 2.758 4.563
Sg CvA (P<.001) 2.441 1.539 3.344
CvM (P=.720) 0.160 -0.742 1.063
AvM (P<.001) -2.281 -3.184 -1.378
Sa CvA (P=.018) 1.107 0.205 2.010
CvM (P<.001) 1.632 0.729 2.535
AvM (P=.245) 0.525 -0.378 1.427
Va CvA (P<.001) -9.706 -10.609 -8.804
CvM (P<.001) -9.352 -10.255 -8.450
AvM (P=.430) 0.354 -0.549 1.256
La CvA (P=.289) 0.477 -0.426 1.380
CvM (P<.001) 3.308 2.405 4.210
AvM (P<.001) 2.831 1.928 3.734
Aa CvA (P=.036) 0.969 0.067 1.872
CvM (P<.001) 3.124 2.222 4.027
AvM (P<.001) 2.155 1.252 3.058
Td CvA (P<.001) -2.200 -3.103 -1.297
CvM (P=.003) 1.442 0.539 2.344
AvM (P<.001) 3.642 2.739 4.544
Sm CvA (P=.001) 1.578 0.675 2.481
CvM (P<.001) 6.679 5.776 7.581
AvM (P<.001) 5.101 4.198 6.003
Ss CvA (P=.013) 1.164 0.261 2.066
CvM (P<.001) 1.999 1.097 2.902
AvM (P=.068) 0.836 -0.067 1.738
95% CI
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Figure 25 Differences in the Corrected CT mean estimates for Run 2017-03-07_pma 
Figure 23 represents the differences in corrected CT mean estimates from the original CT values prior to standardization with 16s 
primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and 
lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An 
“x” represents a statistically significant difference from Amixicile and Metronidazole 
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Table 23. Fold estimates for Run 2017-03-07_pma 
 
Antimicrobials Estimate
Pg Amixicile (P=.996) 1.001 0.536 1.872
Metronidazole (P=.005) 2.527 1.352 4.724
Pi Amixicile (P<.001) 0.003 0.002 0.005
Metronidazole (P<.001) 0.002 0.001 0.003
Fn Amixicile (P<.001) 0.004 0.002 0.008
Metronidazole (P<.001) 0.053 0.028 0.099
Sg Amixicile (P<.001) 5.431 2.905 10.154
Metronidazole (P=.720) 1.117 0.598 2.089
Sa Amixicile (P=.018) 2.155 1.152 4.028
Metronidazole (P<.001) 3.099 1.658 5.794
Va Amixicile (P<.001) 0.001 0.001 0.002
Metronidazole (P<.001) 0.002 0.001 0.003
La Amixicile (P=.289) 1.392 0.744 2.602
Metronidazole (P<.001) 9.902 5.297 18.512
Aa Amixicile (P=.036) 1.958 1.047 3.660
Metronidazole (P<.001) 8.719 4.664 16.301
Td Amixicile (P<.001) 0.218 0.116 0.407
Metronidazole (P=.003) 2.716 1.453 5.078
Sm Amixicile (P=.001) 2.986 1.597 5.582
Metronidazole (P<.001) 102.454 54.803 191.538
Ss Amixicile (P=.013) 2.240 1.198 4.188
Metronidazole (P<.001) 3.998 2.138 7.474
95% CI
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Figure 26 Fold estimates for Run 2017-03-07_pma (95% CIs) 
Figure 24 represents the fold change observed for Run 2017-03-07_pma in bacterial species after treatment of either Amixicile or 
Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment
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Run 2017-04-13_184418PMA 
Table 24. Corrected CT mean estimates for Run 2017-04-13_184418PMA 
 
Antimicrobials Estimate
Pg (P<.001) Control 33.14 32.80 33.47
Amixicile-c 35.07 34.59 35.54
Metronidazole-c 35.73 35.26 36.20
Pi (P<.001) Control 17.33 16.99 17.67
Amixicile-cx 24.25 23.92 24.59
Metronidazole-cx 25.99 25.65 26.33
Fn (P<.001) Control 24.65 24.31 24.98
Amixicile-cx 25.78 25.44 26.11
Metronidazole-cx 27.74 27.41 28.08
Sg (P<.001) Control 18.02 17.69 18.36
Amixicile-c 15.76 15.43 16.10
Metronidazole-c 16.29 15.96 16.63
Sa (P<.001) Control 16.36 16.02 16.69
Amixicile-c 15.09 14.75 15.43
Metronidazole-c 15.53 15.20 15.87
Va (P<.001) Control 14.02 13.68 14.35
Amixicile-cx 22.63 22.30 22.97
Metronidazole-cx 25.44 25.10 25.78
La (P<.001) Control 31.05 30.71 31.39
Amixicile-cx 27.29 26.96 27.63
Metronidazole-cx 28.05 27.72 28.39
Aa (P<.001) Control 33.38 33.04 33.72
Amixicile-c 32.14 31.80 32.48
Metronidazole-c 32.68 32.34 33.02
Td (P<.001) Control 29.08 28.75 29.42
Amixicile-cx 29.94 29.60 30.27
Metronidazole-cx 30.74 30.41 31.08
Sm (P=.376) Control 32.57 32.23 32.90
Amixicile 32.64 32.30 32.98
Metronidazole 32.32 31.99 32.66
Ss (P<.001) Control 15.81 15.48 16.15
Amixicile-cx 13.67 13.33 14.01
Metronidazole-cx 14.29 13.95 14.62
95% CI
Corrected CTBacterial 
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Figure 27. Corrected CT mean estimates for Run 2017-04-13_184418PMA (95% CIs) 
Figure 25 represents the average corrected CT values taken of Run 2017-04-13_1184418PMA. ANOVA analysis was performed and 
applied to compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and Metronidazole. 
A “c” represents a statistically significant difference from control and antimicrobial. An “x” represents a statistically significant 
difference from Amixicile and Metronidazole 
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Table 25. Differences in the Corrected CT mean estimates for Run 2017-04-13_184418PMA 
 
Compare Estimate
Pg CvA (P<.001) -1.933 -2.515 -1.351
CvM (P<.001) -2.594 -3.176 -2.012
AvM (P=.053) -0.661 -1.332 0.010
Pi CvA (P<.001) -6.925 -7.402 -6.449
CvM (P<.001) -8.662 -9.138 -8.185
AvM (P<.001) -1.736 -2.213 -1.260
Fn CvA (P<.001) -1.129 -1.605 -0.653
CvM (P<.001) -3.097 -3.573 -2.621
AvM (P<.001) -1.968 -2.444 -1.492
Sg CvA (P<.001) 2.259 1.783 2.736
CvM (P<.001) 1.730 1.254 2.206
AvM (P=.031) -0.529 -1.005 -0.053
Sa CvA (P<.001) 1.267 0.791 1.743
CvM (P=.001) 0.822 0.345 1.298
AvM (P=.066) -0.445 -0.922 0.031
Va CvA (P<.001) -8.617 -9.093 -8.141
CvM (P<.001) -11.423 -11.899 -10.946
AvM (P<.001) -2.805 -3.282 -2.329
La CvA (P<.001) 3.755 3.279 4.231
CvM (P<.001) 2.998 2.522 3.474
AvM (P=.003) -0.757 -1.233 -0.281
Aa CvA (P<.001) 1.240 0.764 1.716
CvM (P=.005) 0.700 0.223 1.176
AvM (P=.028) -0.541 -1.017 -0.064
Td CvA (P=.001) -0.851 -1.328 -0.375
CvM (P<.001) -1.658 -2.134 -1.182
AvM (P=.002) -0.807 -1.283 -0.330
Sm CvA (P=.752) -0.074 -0.551 0.402
CvM (P=.306) 0.242 -0.234 0.719
AvM (P=.184) 0.317 -0.160 0.793
Ss CvA (P<.001) 2.144 1.668 2.621
CvM (P<.001) 1.526 1.050 2.003
AvM (P=.013) -0.618 -1.094 -0.142
95% CI
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Figure 28. Differences in the Corrected CT mean estimates for Run 2017-04-13_184418PMA 
Figure 26 represents the differences in corrected CT mean estimates from the original CT values prior to standardization with 16s primer. ANOVA 
analysis was performed and applied to compare the control group to Amixicile, control group to Metronidazole and lastly compare Amixicile and 
Metronidazole. A “c” represents a statistically significant difference from control and antimicrobial. An “x” represents a statistically significant 
difference from Amixicile and Metronidazole
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Table 26. Fold estimates for Run 2017-04-13_184418PMA 
 
Antimicrobials Estimate
Pg Amixicile (P<.001) 0.262 0.175 0.392
Metronidazole (P<.001) 0.166 0.111 0.248
Pi Amixicile (P<.001) 0.008 0.006 0.011
Metronidazole (P<.001) 0.002 0.002 0.003
Fn Amixicile (P<.001) 0.457 0.329 0.636
Metronidazole (P<.001) 0.117 0.084 0.163
Sg Amixicile (P<.001) 4.788 3.442 6.661
Metronidazole (P<.001) 3.318 2.385 4.615
Sa Amixicile (P<.001) 2.407 1.730 3.348
Metronidazole (P=.001) 1.767 1.271 2.459
Va Amixicile (P<.001) 0.003 0.002 0.004
Metronidazole (P<.001) 0.0004 0.0003 0.0005
La Amixicile (P<.001) 13.501 9.705 18.782
Metronidazole (P<.001) 7.989 5.743 11.114
Aa Amixicile (P<.001) 2.362 1.698 3.286
Metronidazole (P=.005) 1.624 1.167 2.259
Td Amixicile (P=.001) 0.554 0.398 0.771
Metronidazole (P<.001) 0.317 0.228 0.441
Sm Amixicile (P=.752) 0.950 0.683 1.321
Metronidazole (P=.306) 1.183 0.850 1.646
Ss Amixicile (P<.001) 4.421 3.178 6.151
Metronidazole (P<.001) 2.881 2.071 4.008
95% CI
FoldBacterial 
species
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Figure 29. Fold estimates for Run 2017-04-13_184418PMA (95% CIs) 
Figure 27 represents the fold change observed for Run 2017-04-13_184418pma in bacterial species after treatment of either Amixicile 
or Metronidazole. A P Value <.001 represented a statistical significant change in the numbers of bacteria from the control and 
antimicrobial treatment 
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PMA Runs 
Table 27. Differences in the Corrected CT mean estimates for PMA Runs 
 
Compare Estimate
Pg CvA (P=.696) -0.360 -2.175 1.455
CvM (P=.918) -0.089 -1.793 1.615
AvM (P=.777) 0.271 -1.614 2.156
Pi CvA (P<.001) -7.631 -9.257 -6.006
CvM (P<.001) -8.900 -10.525 -7.275
AvM (P=.125) -1.269 -2.894 0.357
Fn CvA (P<.001) -3.691 -5.316 -2.066
CvM (P<.001) -3.493 -5.119 -1.868
AvM (P=.811) 0.197 -1.428 1.823
Sg CvA (P=.002) 2.531 0.905 4.156
CvM (P=.197) 1.065 -0.560 2.691
AvM (P=.077) -1.465 -3.091 0.160
Sa CvA (P=.141) 1.217 -0.409 2.842
CvM (P=.073) 1.487 -0.139 3.112
AvM (P=.743) 0.270 -1.355 1.895
Va CvA (P<.001) -8.529 -10.155 -6.904
CvM (P<.001) -9.898 -11.524 -8.273
AvM (P=.098) -1.369 -2.994 0.256
La CvA (P=.004) 2.377 0.752 4.003
CvM (P<.001) 3.212 1.587 4.837
AvM (P=.312) 0.835 -0.790 2.460
Aa CvA (P=.479) 0.584 -1.042 2.209
CvM (P=.106) 1.337 -0.288 2.963
AvM (P=.361) 0.754 -0.872 2.379
Td CvA (P=.012) -2.094 -3.719 -0.468
CvM (P=.869) 0.136 -1.490 1.761
AvM (P=.008) 2.229 0.604 3.855
Sm CvA (P=.338) 0.791 -0.835 2.416
CvM (P=.003) 2.465 0.839 4.090
AvM (P=.044) 1.674 0.049 3.299
Ss CvA (P=.032) 1.785 0.159 3.410
CvM (P=.030) 1.807 0.181 3.432
AvM (P=.979) 0.022 -1.603 1.647
95% CI
Corrected CTBacterial 
species
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Figure 30. Differences in the Corrected CT mean estimates for PMA Run 
Figure 29 represents the differences in corrected CT mean estimates from the original CT values prior to standardization with 
16s primer. ANOVA analysis was performed and applied to compare the control group to Amixicile, control group to 
Metronidazole and lastly compare Amixicile and Metronidazole. A “c” represents a statistically significant difference from 
control and antimicrobial. An “x” represents a statistically significant difference from Amixicile and Metronidazole 
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